	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S184-PMC2290997	PMC2290997	4/2008	S184-PMC2290997	['in sunlight-related research, there are two main exposures of interest: Vitamin D status, which is measured by the Serum 25(Oh)D level; and personal uvr dose, which involves three fundamental factors: ambient uvr (a function of latitude, altitude, atmospheric Ozone levels, pollution, and time of year), amount of skin exposed (a function of behavioral, cultural, and clothing practices), and skin pigmentation (with dark skin receiving a smaller effective dose to underlying structures than light skin).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('UBERON_0001977', 'blood serum', 115, 'serum'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 121, '25(OH ... D'), ('CHEBI_25812', 'ozone', 260, 'ozone')]
S40-PMC2798111	PMC2798111	12/2010	S40-PMC2798111	['the Vitamin D status of those infants in the control group who received 400\u2009iu/day Vitamin D3Was measured by circulating 25(Oh)D at 1, 4, and 7 months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_73754', 'thiosugar', 83, 'vitamin D3was'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 83, 'vitamin D3was'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 121, '25(OH ... D')]
S28-PMC2821652	PMC2821652	2/2010	S28-PMC2821652	['with respect to Vitamin D, the Placenta and/or Deciduas are active Extrarenal sites of conversion of 25(Oh)D as they contain 1 α -hydroxylase, providing a source of 1,25(Oh)2D for the fetus.']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0001987', 'placenta', 31, 'placenta'), ('UBERON_0002450', 'decidua', 47, 'deciduas'), ('UBERON_0001691', 'external ear', 67, 'extrarenal'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('CHEBI_37958', 'dye', 165, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 167, '25(OH)2D')]"
S126-PMC2821652	PMC2821652	2/2010	S126-PMC2821652	['because maternal circulating 25(Oh)D is not affected by Gestational age per se, the stability of Vitamin D during Pregnancy allowed for analysis of adherence once steady state was achieved throughout Gestation [15,16].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('GO_0007565', 'female pregnancy', 56, 'gestational'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('GO_0007565', 'female pregnancy', 200, 'gestation')]
S5-PMC2963768	PMC2963768	10/2010	S5-PMC2963768	['the proportion of infants with Vitamin D deficiency defined by 25(Oh)D <25 nmol/l was 28% (95% ci 10-45), 59% (95% ci 40-78) had 25(Oh)D<40 nmol/l, and all were below 80 nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 63, '25 ... OH ... D'), ('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D')]
S44-PMC2963768	PMC2963768	10/2010	S44-PMC2963768	['estimates of the prevalence of Vitamin D deficiency were based on the proportion of participants with 25(Oh)D lower than pre-specified cut-offs (<25 nmol/l, <40 nmol/l, and <80 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D')]
S50-PMC2963768	PMC2963768	10/2010	S50-PMC2963768	"[""other than age and 25(Oh)D, which were compared across groups by one-way analysis of variance, the statistical significance of bivariate associations between the Vitamin D status and the maternal, infant or household characteristics in the entire sample (n=74) was assessed by non-parametric tests, including chi-square tests, mann-u whitney tests, and spearman's rank correlation coefficient.""]"	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 19, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 19, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
S82-PMC2963768	PMC2963768	10/2010	S82-PMC2963768	['comparison of selected characteristics of infants and toddlers categorized by Vitamin D status in sylhet, bangladeshcharacteristics25(Oh)D <25 nmol/l25(Oh)d ≥25 nmol/lp valueno.2450mean 25(Oh)D±sd16.3±5.840.5±11.8<0.001age (mean days±sd)71.3±43.4136.6±126.7<0.001<6 months23 (96)39 (78)0.051boys21 (88)40 (80)0.427birth-order (median±iqr)2±4.52±50.455anthropometric indicators\xa0\xa0underweight11 (46)25 (48)0.861\xa0\xa0stunted10 (42)16 (32)0.415\xa0\xa0low body mass index14 (58)20 (40)0.138age of mothers (mean years±sd)23.7±5.624.8±5.30.410years of schooling of mother (median±iqr)1.5±6.55±60.613years of schooling of father (median±iqr)0±54±50.177family owns their own homestead14 (58)32 (64)0.638manufactured housing materials (i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 133, '(OH)D'), ('CHEBI_33310', 'neon atom', 151, '(OH)'), ('CHEBI_71657', 'versiconol acetate', 186, '25(OH)D')]
S3-PMC3004407	PMC3004407	12/2010	S3-PMC3004407	['a single Blood sample was taken to measure circulating 25(Oh)D as indicator of Vitamin D status [25(Oh)D < 20\u2009ng/ml (50\u2009nmol/l deficiency; <32\u2009ng/ml (80\u2009nmol/l) insufficiency].']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 99, '(OH ... D')]
S36-PMC3004407	PMC3004407	12/2010	S36-PMC3004407	['Blood was processed and Serum separated for later analysis for total circulating 25-Hydroxy-Vitamin D [25(Oh)D], Serum calcium, phosphorus, and creatinine, and intact Parathyroid hormone (pth).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0001977', 'blood serum', 24, 'serum'), ('CHEBI_70487', '(-)-sanguinolignan C', 81, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('UBERON_0001132', 'parathyroid gland', 167, 'parathyroid')]
S92-PMC3004407	PMC3004407	12/2010	S92-PMC3004407	['Vitamin D status as measured by 25(Oh)D was also analyzed by season: after controlling for race, there was no significant evidence of seasonal variation in the prevalence of Vitamin D insufficiency and/or deficiency in this population.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
S97-PMC3004407	PMC3004407	12/2010	S97-PMC3004407	['after controlling for race, Prenatal/multivitamin use (containing 400\u2009iu Vitamin D/day) was not associated with 25(Oh)D concentration ( p = .11).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 81, 'D'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 112, '25(OH)D')]
S14-PMC3257641	PMC3257641	3/2010	S14-PMC3257641	['both sunlight-derived (Vitamin D3) or Ingested (Vitamin D2Or Vitamin D3) Vitamin D are transported to the Liver where 25-hydroxylase enzymes catalyze conversion to the primary storage form (and the usual Serum measure of Vitamin D status), 25-Hydroxyvitamin D (25(Oh)D) [4].']	N/A	N/A	[('CHEBI_33279', 'vitamin D5', 23, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 23, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 38, 'ingested'), ('CHEBI_27329', 'xanthosine phosphate', 48, 'vitamin D2or'), ('PR_000017209', 'utrophin', 48, 'vitamin D2or'), ('CHEBI_33279', 'vitamin D5', 61, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 61, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0002107', 'liver', 106, 'liver'), ('UBERON_0001977', 'blood serum', 204, 'serum'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 240, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 261, '25(OH)D')]
S3-PMC3271033	PMC3271033	1/2012	S3-PMC3271033	['among 38 infants who completed a 3 month Vitamin D supplementation intervention, provision of 400 iu/day of Vitamin D increased final 25(Oh)D to a higher level in non-hispanic caucasian compared to hispanic infants.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 134, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 134, '25 ... OH ... D')]
S4-PMC3271033	PMC3271033	1/2012	S4-PMC3271033	['there was no significant relationship between Cord Serum 25(Oh)D and bmc or bmd in the first week of Life (n = 49) or after 3 months of Vitamin D supplementation.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 46, 'cord'), ('UBERON_0001977', 'blood serum', 51, 'serum'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 57, '25(OH)D'), ('UBERON_0000104', 'life cycle', 101, 'life'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S106-PMC3277098	PMC3277098	12/2011	S106-PMC3277098	['Pregnancy\nduring Pregnancy the foetus is exposed to Vitamin D through Cord Blood supply and the ability of 25(Oh)D and 24,25(Oh)d to cross the Placenta [23].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 17, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 70, 'cord'), ('UBERON_0000178', 'blood', 75, 'blood'), ('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('CHEBI_51686', 'haematoxylin', 124, '(OH'), ('UBERON_0001987', 'placenta', 143, 'placenta')]
S159-PMC3347028	PMC3347028	3/2012	S159-PMC3347028	['during Pregnancy, supplementation with the current standard amount of Vitamin D in Prenatal Vitamins—400 iu (10 μg) Vitamin D/day—has minimal effect on circulating 25(Oh)D concentrations in the mother and her infant at term [6,124].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 92, 'vitamins'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 170, 'D')]
S206-PMC3347028	PMC3347028	3/2012	S206-PMC3347028	['no differences were noted between groups in baseline 25(Oh)D ( p = 0.24), but differences between groups were noted in Vitamin D status within one month of Delivery ( p< 0.0001) and in Cord Blood ( p = 0.0001), with improved status in the 4000-iu group overall.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 53, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0007567', 'parturition', 156, 'delivery'), ('UBERON_0002240', 'spinal cord', 185, 'cord'), ('UBERON_0000178', 'blood', 190, 'blood')]
S448-PMC3407995	PMC3407995	7/2012	S448-PMC3407995	['not a single adverse event was attributed to Vitamin D supplementation or circulating 25(Oh)D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 89, 'OH ... D')]
S5-PMC3513049	PMC3513049	2/2012	S5-PMC3513049	['household Pets were assessed during Pregnancy and Serum level of 25 (Oh)D (25-Hydroxyvitamin D) in Cord Blood was used as the measure of Vitamin D and a marker of maternal level.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 10, 'pets'), ('GO_0007565', 'female pregnancy', 36, 'pregnancy'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 65, '25 (OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 75, '25-hydroxyvitamin D'), ('UBERON_0002240', 'spinal cord', 99, 'cord'), ('UBERON_0000178', 'blood', 104, 'blood'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S204-PMC3552819	PMC3552819	12/2012	S204-PMC3552819	['this was not due to Vitamin D toxicity because her [25(Oh)D] at the time was 47 nmol/l and the [Ca] rapidly and spontaneously normalized.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('CHEBI_32588', 'potassium chloride', 96, 'Ca')]
S6-PMC3641012	PMC3641012	4/2013	S6-PMC3641012	['in the Vitamin D group, 95% of neonates and 100% of mothers attained 25(Oh)D\u2009>50\xa0nmol/l, versus 21% mothers and 19% of neonates in the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 69, '25(OH ... D')]
S95-PMC3641012	PMC3641012	4/2013	S95-PMC3641012	['as a per-protocol sensitivity analysis, change in mean 25(Oh)D over time was modeled as a function of cumulative dose (micrograms) of Vitamin D actually administered.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
S121-PMC3641012	PMC3641012	4/2013	S121-PMC3641012	['analysis shown included participants who contributed 25(Oh)D measurements beyond baseline (n\u2009=\u200974 and n\u2009=\u200973 in Placebo and Vitamin D groups, respectively).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000005060', 'calpastatin', 53, '25 ...'), ('PR_000006444', 'diacylglycerol kinase delta', 59, 'D'), ('CHEBI_26130', 'biological pigment', 112, 'placebo'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S123-PMC3641012	PMC3641012	4/2013	S123-PMC3641012	['with respect to longitudinal analyses of changes in 25(Oh)D over time, 206/219 Serum specimens (93.5%) in the Vitamin D group and 201/213 (94.4%) specimens in the placebo group were preceded by 100% dose adherence.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 52, '25(OH ... D'), ('UBERON_0001977', 'blood serum', 79, 'serum'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S124-PMC3641012	PMC3641012	4/2013	S124-PMC3641012	['3proportions shown were calculated among participants who contributed 25(Oh)D measurements beyond baseline (74 in placebo group or 73 in the Vitamin D group); p value for chi-square test for proportions.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D')]
S130-PMC3641012	PMC3641012	4/2013	S130-PMC3641012	['the highest 25(Oh)D value in any participant was 200\xa0nmol/l, observed in a Vitamin D group participant at Delivery; concurrently, her other biochemistry were normal (adj-ca, 2.47\xa0mmol/l; Urine ca:cr, 0.23\xa0mmol/mmol).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 12, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 18, 'D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007567', 'parturition', 106, 'delivery'), ('UBERON_0001088', 'urine', 187, 'urine')]
S157-PMC3641012	PMC3641012	4/2013	S157-PMC3641012	['point (nmol/l) 45.5[41.0, 49.9]44.4[39.7, 49.1]42.1[39.1, 45.1]difference in 25(Oh)D between groups at day 0 (nmol/l) –1.1[−5.3, 7.6]– decay rate (days-1or mcg-1) 0.04[0.03, 0.05]0.04[0.03, 0.05]0.0003[0.0002, 0.0004]δ25(Oh)D at steady-state in Placebo group (nmol/l) –−7.1[−12.3, -1.9]– effect of Vitamin D on δ25(Oh)D at steady-state (nmol/l) 94.4[83.9, 104.9]101.6[89.7, 113.4]398.3[88.7, 107.9]attained steady-state 25(Oh)D (nmol/l) 139.9[130.1, 149.6]138.8[127.4, 150.2]140.4[131.2, 149.6]adjusted r20.720.750.75 aic –3907.23904.4\n180 participants in the Vitamin D group, contributing 220 specimens.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 77, '25(OH ... D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 221, 'OH)D'), ('CHEBI_26130', 'biological pigment', 245, 'placebo'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 314, '(OH)D'), ('CHEBI_17792', 'organohalogen compound', 423, 'OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 426, 'D'), ('CHEBI_27300', 'vitamin D', 560, 'vitamin D')]
S158-PMC3641012	PMC3641012	4/2013	S158-PMC3641012	['negative exponential model (Vitamin D group): [25( Oh ) D]t\u2009=\u2009[25( Oh ) D]t \u2009=\u20090\u2009+\u2009 a1(1\u2009−\u2009 e−\u2009 kt); where t is time, a is the δ25(Oh)D (where δ is the change from baseline) at steady-state in the Placebo group, and k is the decay rate to the asymptote.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 47, '25( OH ) D'), ('CHEBI_71657', 'versiconol acetate', 63, '25( OH ) D'), ('CHEBI_33010', 'chromide(1-)', 130, '(OH)D'), ('CHEBI_26130', 'biological pigment', 197, 'placebo')]
S160-PMC3641012	PMC3641012	4/2013	S160-PMC3641012	['negative exponential model (both groups):\n[25( Oh ) D]t\u2009=\u2009[25( Oh ) D]t \u2009=\u20090\u2009+\u2009 β \u2009g\u2009+\u2009( gd \u2009+\u2009 a0)(1\u2009−\u2009 e−\u2009 kt); where t is time, a is the δ25(Oh)D at steady-state in the Placebo group, k is the decay rate to asymptote, g is group assignment and d is the difference in δ25(Oh)D between groups at steady-state,\n3difference in δ25(Oh)D between Placebo and Vitamin D groups at modeled steady-state.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 43, '25( OH ) D'), ('CHEBI_71657', 'versiconol acetate', 59, '25( OH ) D'), ('CHEBI_33010', 'chromide(1-)', 143, '(OH)D'), ('CHEBI_26130', 'biological pigment', 172, 'placebo'), ('CHEBI_33010', 'chromide(1-)', 273, '(OH)D'), ('CHEBI_33010', 'chromide(1-)', 329, '(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 333, 'D'), ('CHEBI_26130', 'biological pigment', 343, 'placebo'), ('CHEBI_27300', 'vitamin D', 355, 'vitamin D')]
S213-PMC3641012	PMC3641012	4/2013	S213-PMC3641012	['discussion\namong Pregnant women with relatively low average baseline Vitamin D status in dhaka, 3rd-Trimester Vitamin D3 supplementation (35,000\xa0iu/week) significantly raised maternal and neonatal (Cord Blood) Serum 25(Oh)D concentrations above the iom cut-off for sufficiency (50\xa0nmol/l) in virtually all participants without inducing hypercalcemia or other apparent short-term clinical adverse effects.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'pregnant'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 100, 'trimester'), ('CHEBI_33279', 'vitamin D5', 110, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 110, 'vitamin D3'), ('UBERON_0002240', 'spinal cord', 198, 'cord'), ('UBERON_0000178', 'blood', 203, 'blood'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 216, '25(OH ... D')]
S91-PMC3659910	PMC3659910	1/2013	S91-PMC3659910	['hypercalciuria due to excessive Vitamin D intakes is always accompanied by circulating 25(Oh) D concentrations >250nmol/l (100 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 87, '25(OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 94, 'D')]
S7-PMC3668200	PMC3668200	5/2013	S7-PMC3668200	['in the Kidney, 25(Oh)D, the nutritional indicator of Vitamin D, is hydroxylated into 1,25-Dihydroxyvitamin D (1,25-Oh2-d).']	N/A	N/A	[('UBERON_0002113', 'kidney', 7, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_67472', '15-epi-lupulin B', 85, '1,25-dihydroxyvitamin D'), ('CHEBI_16412', 'lipopolysaccharide', 115, 'OH2')]
S35-PMC3668200	PMC3668200	5/2013	S35-PMC3668200	['when large amounts of Vitamin D (1,000 iu/day) are supplemented during the last trimester to achieve 25(Oh)D concentrations of 50 nmol/l in Pregnant woman, the Vitamin D concentration in the Cord Blood is consequently increased.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 191, 'cord'), ('UBERON_0000178', 'blood', 196, 'blood')]
S85-PMC3691177	PMC3691177	6/2013	S85-PMC3691177	['model adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in Pregnancy, exclusive breast-feeding to four months, any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education and baseline concentration of 25(Oh)D in maternal Blood.10.1371/journal.pone.0066627.t004\n\ncaption (table-wrap): table 4\nclinical outcomes at age three years.controlbolus Vitamin drror p aor† p (%)(%)(95% ci)(95% ci)(95% ci)wheeze ever14/50 (28)15/52 (29)1.03 (0.56, 1.91)1.04 (0.44, 2.47)0.931.17 (0.44, 3.10)0.75recurrent wheezing7/50 (14)9/52 (17)1.24 (0.50 (3.07)1.29 (0.44, 3.77)0.651.91 (0.53, 6.75)0.31wheezing in the last year8/50 (16)9/52 (17)1.08 (0.45, 2.58)1.10 (0.39, 3.12)0.861.29 (0.40, 4.15)0.66wheeze with positive api7/50 (14)9/51 (18)1.26 (0.51, 3.12)1.32 (0.45, 3.86)0.622.01 (0.58, 6.99)0.27any Bronchodilator use4/49 (8)14/48 (29)3.57 (1.27, 10.09)4.63 (1.40, 15.34)0.008*5.43 (1.39, 21.20)0.02*eczema ever15/49 (31)15/48 (31)1.02 (0.56, 1.85)1.03 (0.44, 2.44)0.950.86 (0.32, 2.28)0.76eczema in the last year7/49 (14)9/48 (19)1.31 (0.53, 3.24)1.39 (0.47, 4.08)0.551.97 (0.47, 8.27)0.36atopy7/27 (26)7/32 (22)0.84 (0.34, 2.11)0.80 (0.24, 2.66)0.720.31 (0.05, 1.83)0.20allergic rhinitis7/49 (14)4/46 (9)0.61 (0.19, 1.94)0.57 (0.16, 2.10)0.400.91 (0.20, 4.11)0.90food allergy diagnosed3/49 (6)4/47 (9)1.36 (0.32, 5.78)1.43 (0.30, 6.75)0.651.31 (0.24, 7.18)0.76>4 urti/year7/50 (14)9/48 (19)1.34 (0.54, 3.31)1.42 (0.48, 4.17)0.531.72 (0.49, 6.04)0.39lrti ever11/50 (22)17/47 (36)1.64 (0.86, 3.14)2.01 (0.82, 4.92)0.122.87 (1.03, 8.03)0.05*primary health care recordrecurrent wheeze3/31 (10)6/34 (18)1.82 (0.50, 6.68)2.00 (0.46, 8.80)0.351.85 (0.36, 9.66)0.47eczema6/31 (19)5/34 (15)0.76 (0.26, 2.24)0.72 (0.20, 2.64)0.620.63 (0.11, 3.59)0.60food allergy2/31 (7)0/34 (0)0.0 (-, -) ----\nbolus Vitamin D versus control.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 314, '25(OH)D'), ('UBERON_0000178', 'blood', 334, 'blood'), ('CHEBI_33229', 'vitamin (role)', 455, 'Vitamin'), ('CHEBI_60874', 'phenylacetylglycine(1-)', 900, 'bronchodilator'), ('CHEBI_27300', 'vitamin D', 1893, 'vitamin D')]
S66-PMC3702245	PMC3702245	6/2013	S66-PMC3702245	['these subjects with very low Vitamin D status were started on 800 iu/day of Vitamin D, increased to 1600 iu/day at 36 weeks’ Gestation if Serum 25(Oh)D was still low.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'gestation'), ('UBERON_0001977', 'blood serum', 138, 'serum'), ('CHEBI_71657', 'versiconol acetate', 144, '25(OH)D')]
S85-PMC3702245	PMC3702245	6/2013	S85-PMC3702245	['similarly, 82%, 71%, and 50%, respectively, of the mothers on 4000 iu, 2000 iu, and 400 iu of Vitamin D daily achieved a Serum 25(Oh)D concentration >80 nmol/l ( p = 0.0001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 127, '25(OH)D')]
S117-PMC3705320	PMC3705320	3/2013	S117-PMC3705320	['there was no significant association between baseline Vitamin D status and ∆[25(Oh)D] (data not shown).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D')]
S134-PMC3705320	PMC3705320	3/2013	S134-PMC3705320	['her albumin-adjusted [ca] of 2.61 mmol/l declined to 2.39 mmol/l in a repeat specimen on the same day, the illness was self-limited, and there was no other biochemical or clinical evidence of Vitamin D toxicity; furthermore, the participant continued to receive the supplement and had increasing [25(Oh)D] (range, 52 to 98 nmol/l during follow-up) but did not develop any further episodes of hypercalcemia or elevations in Urine ca:cr.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 297, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 303, 'D'), ('UBERON_0001088', 'urine', 423, 'urine')]
S164-PMC3705320	PMC3705320	3/2013	S164-PMC3705320	['this population was more Vitamin D-replete at baseline (mean [25(Oh)D] = 60 nmol/l) compared to the present study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D')]
S3-PMC3773018	PMC3773018	4/2013	S3-PMC3773018	['we defined fs as specific Ige ≥0.35kua/l to any of eight common Food Allergens; and persistently low Vitamin D status as Cord Blood 25(Oh)D <11ng/ml and Postnatal 25(Oh)D <30ng/ml.']	N/A	N/A	[('GO_0071743', 'IgE immunoglobulin complex, circulating', 26, 'IgE'), ('CHEBI_33290', 'food', 64, 'food'), ('CHEBI_33663', 'cyclic hydrocarbon', 69, 'allergens'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 121, 'cord'), ('UBERON_0000178', 'blood', 126, 'blood'), ('CHEBI_33010', 'chromide(1-)', 134, '(OH)D'), ('GO_0007567', 'parturition', 153, 'postnatal'), ('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 169, 'D')]
S45-PMC3773018	PMC3773018	4/2013	S45-PMC3773018	['similarly, the proportions of children with low Vitamin D status at Birth (i.e., <11ng/ml), <1year, 1–2 years, and 2–3 years (i.e., <30ng/ml) were 38%, 29%, 36%, and 40%, respectively; and the correlation coefficients between Cord Blood 25(Oh)D concentrations and 25(Oh)D measures up to age 1 year, 1–2 years, and 2–3 years were 0.28, 0.39, and 0.63, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007567', 'parturition', 68, 'birth'), ('UBERON_0009472', 'axilla', 226, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 237, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 237, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 264, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 264, '25(OH ... D')]
S6-PMC3873449	PMC3873449	12/2013	S6-PMC3873449	['the prevalence of Vitamin D deficiency (25(Oh)D < 50 nmol/l) was 96.8% and almost half (44.8%) of women were severely Vitamin D deficiency (25(Oh)D < 25 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 140, '25(OH)D')]
S90-PMC3873449	PMC3873449	12/2013	S90-PMC3873449	['Serum 25(Oh)D levels and prevalence of Vitamin D deficiency or insufficiency in Pregnant women\nthe mean Serum 25(Oh)D concentration of women (n 125) was 28.4 ± 9.5; (range 15.1 - 57.1) nmol/l.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('UBERON_0001977', 'blood serum', 104, 'serum'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D')]
S95-PMC3873449	PMC3873449	12/2013	S95-PMC3873449	['age, Gestational age, weight, height, pre-Pregnant bmi, income, duration of walking and duration of computer usage were not different between the two groups.10.1371/journal.pone.0085081.t002\n\ncaption (table-wrap): table 2\nmaternal characteristics of all subjects by Vitamin D group.descriptivewomen with 25(Oh)D<25 nmol/lwomen with 25(Oh)D≥25 nmol/lpnumber (n, %)56 (44.8)69 (55.2)___age (years, sd)28.1 (2.67)28.7 (3.02)p = 0.206gestational age (weeks, sd)17.0 (1.26)16.8 (1.11)p = 0.239height (cm, sd)161.9 (3.26)161.2 (4.03)p = 0.326weight (kg, sd)58.3 (8.37)57.6 (7.62)p = 0.616pre-Pregnant weight (kg, sd)53.4 (6.81)52.9 (6.65)p = 0.648pre-Pregnant bmi (kg/m2, sd)20.4 (2.49)20.3 (2.34)p = 0.902assoc.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 304, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('GO_0007565', 'female pregnancy', 586, 'pregnant'), ('GO_0007565', 'female pregnancy', 645, 'pregnant')]
S116-PMC3873449	PMC3873449	12/2013	S116-PMC3873449	['over 90% of women had Vitamin D deficiency (< 50nmol/l) and none of them reached normal 25(Oh)D concentrations (≥ 75 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D')]
S193-PMC3873449	PMC3873449	12/2013	S193-PMC3873449	['better educated women had higher Serum 25(Oh)D concentrations and lower rates of severe Vitamin D deficiency.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 33, 'serum'), ('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S154-PMC4113768	PMC4113768	7/2014	S154-PMC4113768	['participants completed a sleep questionnaire (the pittsburgh sleep quality index; psqi n = 27 c; n = 13 a), and gave fasted Blood samples for hplc measurement of 25-Hydroxy Vitamin D (25(Oh)D) ( n = 27 c; n = 14 a).']	N/A	N/A	[('UBERON_0000178', 'blood', 124, 'blood'), ('CHEBI_43141', '3-hydroxypropoxy group', 162, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D')]
S217-PMC4113768	PMC4113768	7/2014	S217-PMC4113768	['at each visit, Blood was taken for Serum 25(Oh)D and Vitamin D binding protein quantification, full Blood count, whole-Blood immunophenotyping by flow cytometry and in vitro Infection with hiv-1, followed by functional flow cytometry.']	N/A	N/A	[('UBERON_0000178', 'blood', 15, 'blood'), ('UBERON_0001977', 'blood serum', 35, 'serum'), ('CHEBI_71657', 'versiconol acetate', 41, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 41, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('UBERON_0000178', 'blood', 100, 'blood'), ('UBERON_0000178', 'blood', 119, 'blood'), ('GO_0007586', 'digestion', 174, 'infection')]
S238-PMC4113768	PMC4113768	7/2014	S238-PMC4113768	['the adjusted rr of lrti for Individuals with Vitamin D deficiency (25(Oh)D < 25 nmol/l) in comparison to the referent category (>50 nmol/l) was 1.32 (95% confidence interval (ci) 1.00,1.73).']	N/A	N/A	[('NCBITaxon_1', 'root', 28, 'individuals'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 67, '25(OH)D')]
S380-PMC4113768	PMC4113768	7/2014	S380-PMC4113768	['Serum 25(Oh)D concentrations (measured via lc-tandem ms) was the primary outcome and Serum Ca, pth, 1,25(Oh)2D, 24,25(Oh)2D, Vitamin D binding protein and free 25(Oh)D were exploratory outcomes.']	N/A	N/A	"[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 12, 'D'), ('UBERON_0001977', 'blood serum', 85, 'serum'), ('CHEBI_32588', 'potassium chloride', 91, 'Ca'), ('CHEBI_63056', 'zinc cation', 102, '25(OH'), ('CHEBI_66526', 'strongylin A', 108, '2D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 115, '25(OH)2D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 160, '25(OH)D')]"
S567-PMC4113768	PMC4113768	7/2014	S567-PMC4113768	['results: 260 Pregnant women were randomised to placebo ( n = 87), lower dose ( n = 87) or higher dose ( n = 86) vitamin D. in comparison with placebo, Serum 25(Oh)D concentrations were higher during Pregnancy and infancy in both the lower and higher dose Vitamin D groups.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('UBERON_0001977', 'blood serum', 151, 'serum'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 160, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 163, 'D'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S744-PMC4113768	PMC4113768	7/2014	S744-PMC4113768	['background: laboratory measurement of Serum 25-Hydroxy Vitamin D [25(Oh)D] concentration is used to assess an Individual’s Vitamin D status.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 38, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 44, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('NCBITaxon_1', 'root', 110, 'individual'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D')]
S765-PMC4113768	PMC4113768	7/2014	S765-PMC4113768	['methods: Serum 25-Hydroxy Vitamin D (25(Oh)D) was quantified by hplc-ms/ms at 5–7 weeks of age in 253 hiv-infected and 948 hiv-exposed (uninfected) infants enrolled in a randomized trial of multivitamins (not including Vitamin D) conducted in tanzania during 2004–2007.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 15, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 37, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 219, 'vitamin D')]
S790-PMC4113768	PMC4113768	7/2014	S790-PMC4113768	['methods: a549 cells were cultured and mono-layers were pre-treated with 25-Hydroxy Vitamin D (25(Oh)D), 1,25-Dihydroxy Vitamin D (1,25(Oh)2D) or vehicle (0.1% Ethanol) at a concentration of 10−7m for 48 h. cells were then stimulated with media, rhinovirus-16 (moi 1), filtered rv-16 or uv-inactivated rv-16 for 6 h. supernatants were collected for analysis by multiplex elisa, and cells were Lysed for mrna analysis by rt-pcr.']	N/A	N/A	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 72, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 94, '25(OH)D'), ('CHEBI_50050', 'cystinyl group', 108, '-dihydroxy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 130, '1,25(OH)2D'), ('CHEBI_16236', 'ethanol', 159, 'ethanol'), ('GO_0019835', 'cytolysis', 392, 'lysed')]
S964-PMC4113768	PMC4113768	7/2014	S964-PMC4113768	['results: mean Serum 25(Oh)D concentration was 45.4 nmol/l (sd 25.3), and 171/278 (61.5%) participants were Vitamin D deficient.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 14, 'serum'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 20, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
S1016-PMC4113768	PMC4113768	7/2014	S1016-PMC4113768	['there were no associations between maternal Serum 25(Oh)D or maternal or infant Vitamin D supplementation and any of the gross motor outcomes specified.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 44, 'serum'), ('CHEBI_71657', 'versiconol acetate', 50, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 50, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S1157-PMC4113768	PMC4113768	7/2014	S1157-PMC4113768	['; de jongh, r.t.; den heijer, m.; visser, m.; merlijn, t.; lips, p.; van schoor, n.m.\nbackground: Vitamin D status is currently diagnosed by measuring Serum 25-Hydroxy Vitamin D (25(Oh)D).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 98, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 151, 'serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 157, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D')]
S1661-PMC4113768	PMC4113768	7/2014	S1661-PMC4113768	['concentrations of 25-Hydroxy Vitamin D (25(Oh)D), 1Α,25-Dihydroxy Vitamin D (1,25(Oh)2D), 24r,25-Dihydroxy Vitamin D (24,25(Oh)2D) and 4Β,25-Dihydroxy Vitamin D (4,25(Oh)2d) were determined in Serum samples collected at follow-up and at the time of tb diagnosis.']	N/A	N/A	"[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 18, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_50341', '1-hydroxyethyl group', 50, '1α,25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 79, '25(OH)2D'), ('CHEBI_43141', '3-hydroxypropoxy group', 94, '25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 121, '25(OH)2D'), ('CHEBI_83121', 'decyl hydrogen sulfate', 135, '4β,25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('CHEBI_51686', 'haematoxylin', 166, '(OH'), ('UBERON_0001977', 'blood serum', 193, 'serum')]"
S1714-PMC4113768	PMC4113768	7/2014	S1714-PMC4113768	['results: the prevalence of Vitamin D deficiency (Serum 25-Hydroxy Vitamin D concentration [25(Oh)D]<50 nmol/l) was 54%; median Serum 25(Oh)D concentration was 47 nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('UBERON_0001977', 'blood serum', 49, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 55, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('UBERON_0001977', 'blood serum', 127, 'serum'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 133, '25(OH)D')]
S2426-PMC4113768	PMC4113768	7/2014	S2426-PMC4113768	['methods: the 25(Oh)D (Vitamin D) level of tb patients diagnosed at two south london hospitals between 2004 and 2012 was collected retrospectively from electronic hospital records ( n = 728).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
S2548-PMC4113768	PMC4113768	7/2014	S2548-PMC4113768	['results: Serum Calcium concentrations increased with 0.0008 mmol/l per increment of 1000 iu/day Vitamin D ( p -value < 0.008) and with 0.0001 mmol/l per increase of 1 nmol/l 25(Oh)D ( p -value < 0.001).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'Serum'), ('CHEBI_22313', 'alkaline earth metal atom', 15, 'calcium'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 174, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 174, '25(OH)D')]
S2670-PMC4113768	PMC4113768	7/2014	S2670-PMC4113768	['mean (sd) 25(Oh)D changed from 73 (22) nmol/l at baseline to 124(28) nmol/l at 18-months in the Vitamin D group, and from 71(22) to 56(22) nmol/l in the placebo group.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 10, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
S3199-PMC4113768	PMC4113768	7/2014	S3199-PMC4113768	['the prevalence of Vitamin D deficiency (Serum 25(Oh)D < 30 nmol/l) varied significantly with season with 51% and 23% of participants deficient during spring and autumn respectively ( p< 0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('UBERON_0001977', 'blood serum', 40, 'serum'), ('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 46, '25(OH)D')]
S3368-PMC4113768	PMC4113768	7/2014	S3368-PMC4113768	['methods: we first performed a Genome-wide methylation scan using the illumina Human methylation 27 bead-chip on Leukocyte dna of 11 young african american males with severe Vitamin D deficiency (25(Oh)D ≤ 10 ng/ml) and 11 matched controls (25(Oh)D ≥ 30 ng/ml).']	N/A	N/A	[('SO_0001026', 'genome', 30, 'genome'), ('NCBITaxon_10088', 'Mus <genus>', 78, 'Human'), ('CL_0000738', 'leukocyte', 112, 'leukocyte'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 201, 'D'), ('CHEBI_71657', 'versiconol acetate', 240, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 246, 'D')]
S3370-PMC4113768	PMC4113768	7/2014	S3370-PMC4113768	['a total of 65 young overweight and obese african americans with Vitamin D deficiency (25(Oh)D) ≤20 ng/ml were randomly assigned to receive a supervised monthly oral Vitamin D3Dose of placebo ( n = 16), 18,000 iu (~600 iu/day, the current rda; n = 15), 60,000 iu (~2000 iu/day; n = 17), or 120,000 iu (~4000 iu/day, the deemed tolerable upper Intake level; n = 17).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('CHEBI_27353', 'xylulose', 165, 'vitamin D3dose'), ('GO_0007631', 'feeding behavior', 342, 'intake')]
S29-PMC4169453	PMC4169453	9/2014	S29-PMC4169453	['higher Serum 25(Oh)D levels, prevalence of Vitamin D sufficiency, fat mass loss as well as a lower prevalence of Vitamin D deficiency and decrease of bone mass are expected in Lactating women.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 7, 'serum'), ('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 176, 'lactating')]
S94-PMC4169453	PMC4169453	9/2014	S94-PMC4169453	['a two-factor repeated-measures anova (with box-cox transformation for baseline maternal 25(Oh)D level and infants’ 25(Oh)D levels at Birth, and at 3 and 6 months of age) with time and Vitamin D dose (group) as factors was used to analyze maternal and infants’ Serum 25(Oh)D levels.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 115, '25(OH)D'), ('GO_0007567', 'parturition', 133, 'birth'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0001977', 'blood serum', 260, 'serum'), ('CHEBI_71657', 'versiconol acetate', 266, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 266, '25 ... OH ... D')]
S115-PMC4169453	PMC4169453	9/2014	S115-PMC4169453	['percentage of participants with Serum 25(Oh)D level <20 ng/ml, 20–29.9 ng/ml and >30 ng/ml in both study groups (maternal Vitamin D intake 400 iu/d vs. 1200 iu/d).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 32, 'serum'), ('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 38, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D')]
S116-PMC4169453	PMC4169453	9/2014	S116-PMC4169453	['significant ( p<0.05 ) differences between the study groups are shown on the figures.10.1371/journal.pone.0107708.g003\n\ncaption (fig): figure 3\nmaternal (a) and infants’ (b) Serum 25(Oh)D concentrations at baseline and during Vitamin D supplementation in the study groups (maternal Vitamin D dose: 400 iu/d vs. 1200 iu/d).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 174, 'serum'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 180, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D')]
S127-PMC4169453	PMC4169453	9/2014	S127-PMC4169453	['the mean maternal 25(Oh)D increment was 5.5±8.4 ng/ml in the 400 iu/d group and 10.8±9.4 ng/ml in the 1200 iu/d group ( p \u200a=\u200a0.0009) after 6 months of Vitamin D supplementation.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 18, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 18, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D')]
S175-PMC4169453	PMC4169453	9/2014	S175-PMC4169453	['more than 60% of mothers and newborns were Vitamin D-deficient, and less than 10% of mothers and newborns had 25(Oh)D >30 ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 110, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 116, 'D')]
S176-PMC4169453	PMC4169453	9/2014	S176-PMC4169453	['fortunately, as early as 3 months after implementing Vitamin D supplementation, 25(Oh)D levels increased.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D')]
S207-PMC4169453	PMC4169453	9/2014	S207-PMC4169453	['we observed a slightly higher maternal 25(Oh)D increment during Vitamin D supplementation (5.5 ng/ml in the 400 iu/d group and 11 ng/ml in the 1200 iu/d) due to additional input from diet and endogenous Skin Synthesis[37],[43].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0009697', 'salicylic acid biosynthetic process', 203, 'skin synthesis')]
S6-PMC4231606	PMC4231606	10/2013	S6-PMC4231606	['children underwent a Blood draw for Vitamin D (25(Oh)D), calcium, Parathyroid hormone, and albumin levels.']	N/A	N/A	[('UBERON_0000178', 'blood', 21, 'blood'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 66, 'parathyroid')]
S51-PMC4231606	PMC4231606	10/2013	S51-PMC4231606	['assays for 25(Oh)D, the main circulating form of Vitamin D, were conducted by the hospitals in common laboratory (hicl) at mount sinai hospital in toronto, canada using chemiluminescence immunoassay.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 11, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 13, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 17, 'D'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S57-PMC4231606	PMC4231606	10/2013	S57-PMC4231606	['multiple regression analysis was performed for mean 25(Oh)D including independent variables significantly associated with Vitamin D levels on bivariate analysis or known to influence Vitamin D status.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 58, 'D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D')]
S81-PMC4231606	PMC4231606	10/2013	S81-PMC4231606	['those presently taking Vitamin D drops also had higher 25(Oh)D levels (92.2\u2009±\u200934.6\xa0nmol/l vs. 72.2\u2009±\u200928.2, p\u2009<\u20090.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 55, '25(OH)D')]
S19-PMC4251419	PMC4251419	12/2014	S19-PMC4251419	['Serum 25(Oh)D levels are used to determine Vitamin D status.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
S66-PMC4251419	PMC4251419	12/2014	S66-PMC4251419	['cells from Individuals with various Vitamin D-Binding Protein (Vdbp) variants were studied and for Individuals with the strong 25(Oh)D binding variant, the availability of 25(Oh)D to Dendritic Cells was restricted, resulting in less Dendritic Cell-T Cell interaction.']	N/A	N/A	[('NCBITaxon_1', 'root', 11, 'individuals'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 36, 'vitamin D-binding protein'), ('PR_000017279', 'testis-specific basic protein Y 1', 63, 'VDBP'), ('NCBITaxon_1', 'root', 99, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 127, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 133, 'D'), ('CHEBI_71657', 'versiconol acetate', 172, '25(OH)D'), ('CL_0000451', 'dendritic cell', 183, 'dendritic cells'), ('CL_0000451', 'dendritic cell', 233, 'dendritic cell'), ('GO_0030425', 'dendrite', 233, 'dendritic'), ('CL_0000084', 'T cell', 248, 'T cell')]
S15-PMC4256222	PMC4256222	12/2014	S15-PMC4256222	['during Pregnancy Vitamin D is transported from the mother to the fetus through the Placenta in the form of 25-Hydroxyvitamin D (25(Oh)D), and at Birth the concentration in Umbilical Cord Blood is around 80% of maternal Blood concentration[2].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0001987', 'placenta', 83, 'placenta'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 107, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('GO_0007567', 'parturition', 145, 'birth'), ('UBERON_0002331', 'umbilical cord', 172, 'umbilical cord'), ('UBERON_0000178', 'blood', 187, 'blood'), ('UBERON_0000178', 'blood', 219, 'blood')]
S110-PMC4427001	PMC4427001	4/2015	S110-PMC4427001	['given the high overall prevalence of Vitamin D deficiency, we did not find any statistically significant difference in 25(Oh)D levels between woman with gdm diagnosed by who criteria and controls during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 121, '('), ('PR_000013502', 'parvalbumin alpha', 124, ')D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]
S25-PMC4499946	PMC4499946	7/2015	S25-PMC4499946	['in the absence of maternal Vitamin D supplementation, Postnatal infant 25(Oh)D concentration was low in the Neonatal Period, but gradually increased over the first several months of Life (unpublished observations).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007567', 'parturition', 54, 'postnatal'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 71, '25(OH ... D'), ('UBERON_0007221', 'neonate stage', 108, 'neonatal period'), ('UBERON_0000104', 'life cycle', 182, 'life')]
S32-PMC4499946	PMC4499946	7/2015	S32-PMC4499946	['maternal mean 25(Oh)D was significantly higher at Delivery after receiving Vitamin D versus placebo (134 vs. 39 nmol/l; p< 0.001; n = 133).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 14, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 14, '25(OH ... D'), ('GO_0007567', 'parturition', 50, 'delivery'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S33-PMC4499946	PMC4499946	7/2015	S33-PMC4499946	['there was a parallel difference in Cord 25(Oh)D (103 nmol/l in Vitamin D group vs. 39 nmol/l in placebo group; p< 0.001; n = 132) [16].']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 35, 'cord'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
S75-PMC4598849	PMC4598849	10/2015	S75-PMC4598849	['second, 25(Oh)D levels at Birth cannot represent the Vitamin D status in early Pregnancy.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('GO_0007567', 'parturition', 26, 'birth'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy')]
S63-PMC4632418	PMC4632418	10/2015	S63-PMC4632418	['seven different criteria were used to diagnose gdm and five assay techniques were used to measure Serum 25(Oh)D level.nutrients-07-05398-t001_table 1\n\ncaption (table-wrap): table 1\n\ncharacteristics of observational studies included in this meta-analysis.author and yearlocationstudy typeparticipants( n )gdm( n )gdm criteria *assay methodmean 25(Oh)D nmol/l (sd)prevalencesignificantadjustments**gdmngtmaghbooli (2008) [22]irancross-sectional57952c&cria16.5(10.4)22.9(18.3)70.60%yesa, bclifton-bligh (2008) [23]australiacross-sectional30781adpslc–ms48.6(24.9)55.3(23.3)48%yesa, b, czhang (2008) [24]usnested-case-control17157adaelisa60.4(21.22)75.13(24.21)19.80%yesa, b, c, dfarrant (2009) [16]indiacross-sectional55939c&cria49.3(31.2)46.4(30.9)66%noa, b, e, fsoheilykhah (2010) [25]irancase-control16554c&celisa24.01(20.62)32.2(35.74)78.40%yesnrbaker (2012) [15]usnested-case-control18060nddglc–ms97.0(29.0)86.0(22.0)7.20%yesa, b, e, hmakgoba (2011) [26]ukcase-control24890wholc–ms47.2(26.7)47.6 (26.7)58.80%noa, b, c, d, e, gparlea (2012) [27]canadanested-case-control337118nddgclia56.3(19.4)62.0(21.6)nryesh, ifernandez-alonso (2012) [28]spaincross-sectional46636adaeclianrnr23.40%nrnrparildar (2013) [29]turkeycase-control12244iadpsgclia48.67(23.21)57.16(24.96)43.40%nonrwang (2012) [30]chinanested-case-control400200adaelisa22.4(10.7)25.9(12.3)96.25%yesa, d, jburris (2012) [31]uscross-sectional115568adaclianrnr33.10%nra, b, c, e, h, k, l, m, n, o, p, tperez-ferre (2012) [32]spaincross-sectional26649adaclianrnr59.02%nra, c, d, gzuhur (2013) [33]turkeycross-sectional402234iadpsgeclia30.8(16.3)36.0(16.2)84.30%yesa, b, d, gbener (2013) [34]qatariprospective cohort1873260whorianrnr48.40%nrnrlacroix (2014) [35]canadacross-sectional65554iadpsglc–ms57.5(17.2)63.5(18.9)26.70%yesa, c, d, e, g, r, s, t, umcmanus (2014) [36]canadacase-control7336cdaria77.3(24.3)93.2(19.2)6.85%yesa, bpark (2014) [37]koreaprospective cohort52323c&ceclia49.4(19.4)48(24.8)88.90%noa, b, e, h, g, varnold (2015) [38]usnested-case-control652135adalc–ms59.7(23.5)66.6(22)25.61%yesa, b, c, d, epleskacova (2015) [39]czechcase-control7647whoeiasa28(3.76)31.85(4.62)94.7%nob\nnote: nr, not reported; prevalence: prevalence of Vitamin D deficiency; significant: significant difference in Serum 25(Oh)d between Gestational diabetes mellitus (gdm) & normal Glucose tolerance (ngt).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2203, 'vitamin D'), ('UBERON_0001977', 'blood serum', 2264, 'serum'), ('CHEBI_30778', 'gallic acid', 2270, '25(OH)'), ('GO_0007565', 'female pregnancy', 2286, 'gestational'), ('CHEBI_17234', 'glucose', 2331, 'glucose')]
S46-PMC4632423	PMC4632423	10/2015	S46-PMC4632423	['Plasma samples were used to measure levels of Vitamin A, Vitamin E and Cholesterol by high performance liquid chromatography; copper, zinc, and selenium by inductively coupled Plasma mass spectrometry (agilent technologies, stockport, cheshire, uk sk8 3gr); and 25 Hydroxyvitamin D (25(Oh)D) by tandem mass spectrometry (waters acquity; uplc and tqd, hertfordshire, uk wd6 3sz).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 54, 'A'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin E'), ('CHEBI_16113', 'cholesterol', 71, 'cholesterol'), ('UBERON_0001969', 'blood plasma', 176, 'plasma'), ('CHEBI_67828', 'rel-(3aR,4S,6aS,7R,9aR,10aS)-10a-Hydroxy-7-isopropyl-1,4,9a-trimethyl-4,5,6,6a,7,8,9,9a,10,10a-decahydro-3aH-dicyclopenta[a,d]cycloocten-3-one', 262, '25 hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 283, '25(OH)D')]
S135-PMC4689556	PMC4689556	12/2015	S135-PMC4689556	['association between Prenatal or Postnatal Vitamin D level and healthcare utilisation\nof the 99 offspring with complete e-hr data, Cord levels of 25(Oh)D were available for 79, and 25(Oh)D levels at age three years for 65.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 20, 'prenatal'), ('GO_0007567', 'parturition', 32, 'postnatal'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 130, 'cord'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 180, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 186, 'D')]
S87-PMC4690051	PMC4690051	12/2015	S87-PMC4690051	['median dietary intake of Vitamin D during the second trimester for the whole cohort was 177 iu (range 13.3–772).nutrients-07-05499-t001_table 1\n\ncaption (table-wrap): table 1\n\ncharacteristics of the mothers at enrollment and the children at 2-year assessment (cv2; n = 1020).n %insurance\u2003other insurance48947.9\u2003medicaid, medicare53152.1education\u2003hs diploma or lower56755.6\u2003college or higher degree45344.4marital status\u2003cohabitation60158.9\u2003single41941.1pre-Pregnancy bmi, kg/m2\u2003underweight454.4\u2003normal39738.9\u2003overweight24023.5\u2003obese33833.1alcohol use, yes868.4tobacco use, yes858.3total Pregnancies1\u2003130930.3\u20032–559458.2\u2003>511711.5gestational 25(Oh)D\u2003<20 ng/dl42541.7\u200320.00–29.99 ng/dl44043.1\u2003≥30 ng/dl15515.2 meansd Weeks Of Gestation38.91.725(Oh)D, ng/dl22.38.5maternal age, years26.65.5maternal total iq96.216.4birth weight, z -score0.050.95birth length, z -score0.531.28head circumference, z -score−0.031.34child age at cv2 assessment, months25.01.5cognitive scaled score29.62.6receptive language scaled score29.52.9expressive language scaled score29.92.7\n1includes current Pregnancy and previously completed term and pre-term Pregnancies;2as assessed at 2-year exam (cv2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 456, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 586, 'Pregnancies1'), ('CHEBI_71657', 'versiconol acetate', 640, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 646, 'D'), ('GO_0016055', 'Wnt signaling pathway', 714, 'Weeks of Gestation38'), ('CHEBI_33010', 'chromide(1-)', 741, '(OH)D'), ('GO_0007565', 'female pregnancy', 1075, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1128, 'pregnancies')]
S100-PMC4690051	PMC4690051	12/2015	S100-PMC4690051	['dietary intake of Vitamin D was not associated with scaled scores or mid-Gestational 25(Oh)D levels.nutrients-07-05499-t002_table 2\n\ncaption (table-wrap): table 2\n\nscaled developmental scores by selective characteristics ( n = 1020).Cognitivereceptive languageexpressive languagemeansd p1meansd p1meansd p1race<0.0001<0.0001<0.0001\u2003african-american8.82.28.62.39.32.3\u2003european-american11.02.711.13.111.03.1insurance<0.0001<0.0001<0.0001\u2003other insurance10.42.810.53.110.73.0\u2003medicaid, medicare8.82.18.62.39.22.2education<0.0001<0.0001<0.0001\u2003hs diploma or lower8.92.18.72.49.32.2\u2003college or higher degree10.42.810.53.110.73.0marital status<0.0001<0.0001<0.0001\u2003cohabitation10.12.710.13.010.32.9\u2003single8.82.28.62.39.32.3pre-Pregnancy bmi, kg/m20.00010.00010.0001\u2003under weight9.72.29.92.99.92.6\u2003normal9.92.79.93.110.42.9\u2003overweight9.52.39.42.710.02.6\u2003obese9.22.69.02.79.42.4alcohol use0.00240.0020.007\u2003no9.52.59.42.89.82.6\u2003yes10.33.010.73.610.63.1tobacco use<0.0006<0.0006<0.0006\u2003no9.62.69.62.910.02.7\u2003yes8.72.08.52.78.82.6total Pregnancies0.00060.0290.0028\u2003110.02.99.83.010.32.7\u20032–59.52.49.52.99.82.8\u2003>58.82.28.82.39.42.2gestational diabetes0.100.220.14\u2003missing8.32.19.72.59.71.2\u2003no9.52.69.52.99.92.7\u2003yes10.02.69.93.010.32.9pre-eclampsia0.0670.0230.19\u2003missing9.02.29.62.59.81.6\u2003no9.62.69.62.910.02.7\u2003yes9.12.28.82.49.52.6delivery0.00210.1020.024\u2003pre-term8.82.28.92.99.32.8\u2003full term9.62.69.52.910.02.7gestational 25(oh)d<0.0001<0.0001<0.0001\u2003<20 ng/dl9.12.48.92.59.42.4\u200320.00–29.99 ng/dl9.82.89.73.010.22.9\u2003≥30 ng/dl10.12.410.53.210.42.6\n1p -value for comparison among the subgroups ( i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 85, '25 ... OH ... D'), ('GO_0050802', 'circadian sleep/wake cycle, sleep', 233, 'CognitiveReceptive'), ('GO_0007565', 'female pregnancy', 721, 'Pregnancy'), ('GO_0006412', 'translation', 1025, 'Pregnancies0'), ('CHEBI_37972', 'phosphorus-32 atom', 1410, '25')]
S88-PMC4719746	PMC4719746	1/2016	S88-PMC4719746	['1\n\nproportions of participants with levels of 25(Oh)D 12-\u2009<\u200925\xa0nmol/l and <12\xa0nmol/l at Gestational week 15 and 28\nin early Pregnancy, the values of 25(Oh)D differed between the ethnic groups and remained significant after adjustment for age, parity, season, education and intake of Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 46, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 88, 'gestational'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 149, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]
S93-PMC4719746	PMC4719746	1/2016	S93-PMC4719746	['caption (table-wrap): table 3\n\nlinear regression analysis with Vitamin D [25(Oh)D] at inclusion and Gestational week 28 as dependant variablesat inclusionat Gestational week 28univariate analysismultiple analysisunivariate analysismultiple analysisn\u2009=\u2009735, r2adj.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D'), ('GO_0007565', 'female pregnancy', 100, 'gestational'), ('GO_0007565', 'female pregnancy', 157, 'gestational')]
S98-PMC4719746	PMC4719746	1/2016	S98-PMC4719746	['mean 25(Oh)D values were −17 (95 % ci: −23, −11), −10 (−16, −2.9) and −12 (−20, −3.1) nmol/l lower in south asians, middle easterners and sub-saharan africans compared with western europeans after adjustments for Gestational week at inclusion, age, parity, season, education and Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 5, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 5, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 213, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D')]
S82-PMC4785305	PMC4785305	3/2016	S82-PMC4785305	['aub-mc clinical chemistry laboratory partakes in the quality assurance, evaluation and accreditation by the college of american pathologists43and is a participant in the Vitamin D external quality assurance surveillance (deqas) programme.44\n\ncaption (table-wrap): table\xa01\n\ntrial events and outcomes measurestrial event and outcomes measures11–13\u2005weeks (screening visit)15–18\u2005weeks (visit 1)20\u2005weeks24–28\u2005weeks28–32\u2005weeks (visit 2)37–42\u2005weeks delivery (visit 3)1\u2005month post Partum (visit 4)maternal height✓maternal weight, Blood pressure✓✓✓maternal health and diet assessment✓✓✓maternal 25(Oh)D, crea, ca×××maternal Cell count, ph, mg, alb, Tsh, 1,25(Oh)2D×pth××maternal Glucose (1\u2005h)✓maternal 24\u2005h (or spot) Urine collection for calcium and creatinine××maternal Vitamin D Binding Protein××maternal Genetic pathways of Vitamin D Metabolism×fetal us:\nCrown -Rump✓fetal us:\nFemur length\nabdominal circumference\nHead circumference\nbiparietal diameter✓newborn weight, length, Knee to Heel length apgar score✓Placental weight×Placental studies×newborn 25(Oh)D, ca, pth (Cord Blood)×newborn Genetic pathways of Vitamin D Metabolism×infant bone/fat mass×infant weight and length✓infant health and diet assessment✓\n✓test performed for clinical purpose.']	N/A	N/A	"[('CHEBI_28384', 'vitamin K', 170, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 170, 'Vitamin D'), ('GO_0007567', 'parturition', 473, 'partum'), ('UBERON_0000178', 'blood', 522, 'blood'), ('CHEBI_71657', 'versiconol acetate', 586, '25(OH)D'), ('CL_0000573', 'retinal cone cell', 615, 'cell'), ('CHEBI_17855', 'triglyceride', 640, 'TSH'), ('CHEBI_17996', 'chloride', 646, ','), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 647, '25(OH)2D'), ('CHEBI_17234', 'glucose', 670, 'glucose'), ('UBERON_0001088', 'urine', 708, 'urine'), ('CHEBI_27300', 'vitamin D', 762, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 762, 'vitamin D binding protein'), ('SO_0000704', 'gene', 798, 'genetic'), ('CHEBI_27300', 'vitamin D', 818, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 818, 'vitamin D metabolism'), ('UBERON_0002943', 'lingual gyrus', 849, 'crown -rump✓'), ('UBERON_0000981', 'femur', 871, 'Femur'), ('UBERON_0000033', 'head', 908, 'Head'), ('UBERON_0001465', 'knee', 971, 'knee'), ('UBERON_0015875', 'heel', 979, 'heel'), ('UBERON_0001987', 'placenta', 1003, 'Placental'), ('UBERON_0001987', 'placenta', 1020, 'Placental'), ('CHEBI_71657', 'versiconol acetate', 1046, '25(OH)D'), ('UBERON_0009472', 'axilla', 1064, 'cord blood'), ('SO_0000704', 'gene', 1084, 'genetic'), ('CHEBI_27300', 'vitamin D', 1104, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 1104, 'vitamin D metabolism')]"
S88-PMC4811441	PMC4811441	3/2016	S88-PMC4811441	['in model 2, Vitamin D status was fixed and only baseline 25(Oh)D was included.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 63, 'D')]
S48-PMC4859539	PMC4859539	5/2016	S48-PMC4859539	['using the institute of medicine’s definition of sufficiency (total circulating 25(Oh)D ≥20 ng/ml (50 nmol/l) [25], the cohort also was divided into two groups based on child’s current Vitamin D status, with those with 25(Oh)D concentrations <20 ng/ml (50.0 nmol/l) defined as deficient.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 79, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 218, '25(OH)D')]
S57-PMC4859539	PMC4859539	5/2016	S57-PMC4859539	"[""of infections in the last year [median (range)]1.0 (0.0–5.0)child’s daily Vitamin D intake at time of visit (iu/day)1205.3 ± 109.8 (17.1–512.5)child's 25(Oh)D at time of visit (ng/ml)127.2 ± 9.4 (8.3–61.5)child's Vitamin D status at time of visit\xa0\xa0\xa0\xa0\xa0sufficient (≥20 ng/ml) [n (%)]106 (79.7)\xa0\xa0\xa0\xa0deficient (<20 ng/ml) [n (%)]27 (20.3)total circulating 25(Oh)D (ng/ml) at Birth122.8 ± 9.8 (3.6–47.8)maternal 25(Oh)D (ng/ml) within 1 month prior to Delivery139.2 ± 15.0 (10.0–78.6)maternal 25(Oh)D area under curve, Pregnancy visits 3–71153.1 ± 44.6 (50.1–251.4)\n1mean±std (range)\n\nstudy outcomes\nthe median Cathelicidin concentration for the entire cohort was 28.1 ng/ml, ranging from 5.6 to 3368.6 ng/ml.""]"	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 154, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 157, 'D'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 351, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 351, '25 ... OH ... D'), ('GO_0042750', 'hibernation', 370, 'birth122'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 406, '25(OH)D'), ('GO_0030324', 'lung development', 446, 'delivery139'), ('CHEBI_71657', 'versiconol acetate', 487, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 487, '25(OH)D'), ('GO_0007565', 'female pregnancy', 513, 'pregnancy'), ('CHEBI_3364', 'Canthiumine', 605, 'cathelicidin')]
S54-PMC4929134	PMC4929134	8/2016	S54-PMC4929134	['Plasma concentrations of Retinol, 25(Oh)D, cobalamin, Folic Acid, Transferrin receptor, ferritin, and thyroglobulin were measured to assess child Vitamin A, d, and b12, Folate, iron, and Iodine status.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_26536', 'retinoic acid', 25, 'retinol'), ('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('CHEBI_30751', 'formic acid', 54, 'folic acid'), ('PR_000016293', 'protein-glutamine gamma-glutamyltransferase 2', 66, 'transferrin'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin A'), ('CHEBI_30863', '5-azaorotic acid', 169, 'folate'), ('CHEBI_24859', 'iodine atom', 187, 'iodine')]
S5-PMC4930210	PMC4930210	7/2016	S5-PMC4930210	['25(Oh)D2, 25(Oh)D3, and 3-Epi-25(Oh)D3) were identified in all of the 537 Plasma samples;3-Epi-25(Oh)D3Contributed 5% of the total Vitamin D. the median (iqr) total 25(Oh)D (D2+d3) was 92.7 (30.4) nmol/l and 20% of women had 25(Oh)D concentration < 75 nmol/l.']	N/A	N/A	[('CHEBI_77765', '2,4,6-trihydroxybenzophenone(1-)', 0, '25(OH)D2'), ('CHEBI_62946', 'ammonium sulfate', 10, '25(OH)D3'), ('CHEBI_76959', '19-HEPE', 24, '3-epi-'), ('CHEBI_62946', 'ammonium sulfate', 30, '25(OH)D3'), ('UBERON_0001969', 'blood plasma', 74, 'plasma'), ('CHEBI_86390', '3-pyridylacetic acid', 89, '3-epi-25(OH)D3contributed'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 165, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 171, 'D'), ('CHEBI_37987', 'Cy3 dye', 174, 'D2'), ('CHEBI_71657', 'versiconol acetate', 225, '25(OH)D')]
S110-PMC4930210	PMC4930210	7/2016	S110-PMC4930210	['the relationship between 25(Oh)D and 3-epi-25(oh)D3And Vitamin D intake are shown infig 2a and 2b.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000006317', 'mRNA-decapping enzyme 1A', 49, 'D3and'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
S83-PMC4934634	PMC4934634	11/2015	S83-PMC4934634	['all women receiving the weekly supplement reached Vitamin D sufficiency as assessed by both iom and Endocrine society cut-offs (25(Oh)D) = 47.65 ± 1.11 ng/ml) at the end of the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 100, 'Endocrine'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 128, '25(OH ... D')]
S121-PMC4934634	PMC4934634	11/2015	S121-PMC4934634	['after six weeks, there was a significant increase in Serum 25(Oh)D in the Vitamin D group (+18.51 ± 20.46 ng/ml).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 53, 'serum'), ('CHEBI_71657', 'versiconol acetate', 59, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 59, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
S238-PMC4934634	PMC4934634	11/2015	S238-PMC4934634	['common Gene polymorphisms in 7-Dehydrocholesterol reductase, Cyp2Ri, and Vitamin D binding protein were found to significantly alter Serum 25(Oh)D levels [85].']	N/A	N/A	[('SO_0000704', 'gene', 7, 'gene'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 29, '7-dehydrocholesterol'), ('PR_000006101', 'cytochrome P450 1A1', 61, 'CYP2RI'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0001977', 'blood serum', 133, 'serum'), ('CHEBI_71657', 'versiconol acetate', 139, '25(OH)D')]
S83-PMC4944244	PMC4944244	7/2016	S83-PMC4944244	['caption (table-wrap): table 3\n\ncombination of descriptive and simple logistic regression analysis to show the relationship between risk factors and hypovitaminosis d ( n \u2009=\u2009396)variableserum 25(Oh)D <50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)Serum 25(Oh)D ≥50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)crude or (95 % ci) p valueage(year)c27.91\u2009±\u20093.9529.47\u2009±\u20095.070.91(0.84, 0.99)0.026ethnic groupscmalay296 (96.40)11 (3.60)22.42(9.63, 52.21)<0.001chinese24 (54.50)20 (45.5)1.00indian32 (91.40)3 (8.60)8.89(2.36, 33.40)0.001others6 (60.00)4 (40.00)1.25(0.31, 5.06)0.754education levelcprimary11 (68.80)5 (31.20)1.00secondary136 (91.30)13 (8.70)4.75(1.43, 15.80)0.011tertiary211 (91.30)20 (8.70)4.80(1.52, 15.18)0.008working statusworking275 (91.40)26 (8.60)1.000.252not working83 (87.40)12 (12.60)0.65(0.32, 1.35)household income per monthc3500 (2800,5000)3750 (2500,5250)1.00(1.00, 1.00)0.060household Membersc3 (2,4)3 (2,5)0.90(0.75, 1.07)0.225weeks of Pregnancy at first Antenatal visitc10.0 (8.0,12.0)11.5 (8.0,12.0)0.89(0.77,1.02)0.100parityc0 (0,1)1 (0,1)0.79(0.61, 1.03)0.083last child Birth≤ 2\xa0years111 (89.50)13 (10.50)0.86(0.43,1.75)0.686>2 yearsa247 (90.80)25 (9.20)1.00breastfeedingyes36 (87.80)5 (12.20)0.74(0.27,2.01)0.552nob322 (90.70)33 (9.30)1.00bmi before Pregnant (kg/m2)22.76 (20.00,26.25)22.15 (19.75,26.58)1.02(0.96,1.09)0.499weight at first Antenatal visit (Kg)57.85 (49.30,68.54)57.03 (51.49,65.61)1.01(0.98,1.03)0.569fitzpatrick classificationcskin type i-ii83 (80.60)20 (19.40)1.00skin type iii163 (94.20)10 (5.80)3.93(1.76,8.77)0.001skin type iv-vi112 (93.30)8 (6.70)3.37(1.42,8.03)0.006melanin indices (using mexameter)(0-999.000)306.17 (254.17,373.67)242.83 (181.08, 354.00)1.01(1.00,1.01)0.006sun protection score(0-8)c5 (4,5)3.5 (1,5)1.77(1.42,2.21)<0.001total of respondents exposed to sunlight (10\xa0am-2\xa0pm)yes201 (90.10)22 (9.90)1.00no157 (90.80)16 (9.20)1.07(0.55,2.11)0.836the length of time exposed to sunlight (minutes in week)35 (0,150)55 (0,210)1.00(1.00,1.00)0.570intake of Vitamin D from Food (iu/day)c197.51 (122.70,332.05)263.81 (142.90,460.55)1.00(1.00,1.00)0.042intake of Vitamin D from Food and supplements (iu/day)215.080 (132.93,361.98)302.135 (147.89,515.74)1.00(1.00,1.00)0.064the level of Vitamin D in Foods and supplements (iu/day)<200\xa0iu/day165 (92.70)13 (7.30)1.64(0.82,3.32)0.165≥200\xa0iu/day193 (88.50)25 (11.50)1.00\nor odds ratio, ci confidence interval\np values have been derived from wald tests\narespondents with last child Birth more than 2\xa0years and respondents who did not have previous child (primid)\nbrespondents who did not Breastfeed during Pregnancy and those who did not have children.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 191, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 194, 'OH ... D'), ('UBERON_0001977', 'blood serum', 238, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 247, 'OH ... D'), ('PR_000010433', 'makorin-3', 890, 'membersc3'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('GO_0007567', 'parturition', 961, 'antenatal'), ('GO_0007567', 'parturition', 1080, 'birth'), ('GO_0007565', 'female pregnancy', 1261, 'pregnant'), ('GO_0007567', 'parturition', 1351, 'antenatal'), ('UBERON_0001465', 'knee', 1368, 'kg'), ('CHEBI_27300', 'vitamin D', 2001, 'vitamin D'), ('CHEBI_33290', 'food', 2016, 'food'), ('CHEBI_27300', 'vitamin D', 2104, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 2112, 'D'), ('CHEBI_33290', 'food', 2119, 'food'), ('CHEBI_27300', 'vitamin D', 2227, 'vitamin D'), ('CHEBI_33290', 'food', 2240, 'foods'), ('GO_0007567', 'parturition', 2468, 'birth'), ('GO_0007596', 'blood coagulation', 2574, 'breastfeed'), ('GO_0007565', 'female pregnancy', 2592, 'pregnancy')]
S102-PMC4944244	PMC4944244	7/2016	S102-PMC4944244	['[21] reported that the prevalence of Vitamin D deficiency (Serum 25(Oh)D <25\xa0nmol/l) among Pregnant women in tehran was 70.6\xa0% and the prevalence of severe Vitamin D deficiency (Serum 25(Oh)D <12.5\xa0nmol/l) was 28.8\xa0%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0001977', 'blood serum', 59, 'serum'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 65, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 91, 'pregnant'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('UBERON_0001977', 'blood serum', 178, 'serum'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 184, '25(OH ... D')]
S116-PMC4971719	PMC4971719	8/2016	S116-PMC4971719	['1\n\nconsort diagram\nparticipants characteristics were stratified by possible Vitamin D deficiency (25 (Oh) D <20\xa0ng/ml) for descriptive purposes (table\xa01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 98, '25 (OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 106, 'D')]
S27-PMC5045784	PMC5045784	10/2016	S27-PMC5045784	['we measured 25(Oh)D levels, a combination of 25(Oh)D2And 25(Oh)D3, which represent the best analytes for overall Vitamin D status11using diasorin liaison (diasorin, stillwater, mn, usa), which uses a chemiluminescence immunoassay12to determine Plasma concentrations of 25(Oh)D. for quality control, the laboratory used the us national institute of standards and technology level 1.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 12, '25(OH)D'), ('CHEBI_76948', 'ent-manool', 45, '25(OH)D2and'), ('CHEBI_62946', 'ammonium sulfate', 57, '25(OH)D3'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 244, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 271, '(OH ... D')]
S28-PMC5062906	PMC5062906	10/2016	S28-PMC5062906	['dietary Vitamin D is converted in the Liver to the inactive Metabolite 25-Hydroxyvitamin D, 25(Oh)D, before being converted in the Kidney to the active Metabolite 1,25(Oh)2D.']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('UBERON_0002107', 'liver', 38, 'liver'), ('CHEBI_39382', 'flufenoxuron', 60, 'metabolite'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 71, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('UBERON_0002113', 'kidney', 131, 'kidney'), ('CHEBI_39382', 'flufenoxuron', 152, 'metabolite'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 165, '25(OH)2D')]"
S63-PMC5084041	PMC5084041	10/2016	S63-PMC5084041	['statistical analysis\nrisk factors for Vitamin D deficiency (25(Oh)D <30 nmol/l) [26] were analysed using a multivariable logistic regression analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 66, 'D')]
S65-PMC5084041	PMC5084041	10/2016	S65-PMC5084041	['the 25(Oh)D concentration was adjusted to the predicted yearly mean 25(Oh)D of the function, in order to account for seasonality in Vitamin D status.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
S74-PMC5084041	PMC5084041	10/2016	S74-PMC5084041	['subgroup analyses of the variables relating to Vitamin D deficiency and season-corrected 25(Oh)D change were performed for women Born in africa and asia, using the same models.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 89, '25 ... OH ... D'), ('GO_0007567', 'parturition', 129, 'born')]
S76-PMC5084041	PMC5084041	10/2016	S76-PMC5084041	['also, 25(Oh)D at t1 and tobacco use at t1 were considered as confounders in the regression analysis of season-corrected change in 25(Oh)D.\ncontinuous variables were bmi (kg/m2), Gestational weight gain, dietary Vitamin D intake and age.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 133, 'OH)D'), ('GO_0007565', 'female pregnancy', 178, 'gestational'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
S114-PMC5129897	PMC5129897	10/2016	S114-PMC5129897	['an 8-week clinical trial of 50,000 iu/wk of Vitamin D or placebo was conducted on patients with mdd in iran from october to december 2014.77baseline 25(Oh)D concentrations were 23 ± 15\xa0nmol/l in the placebo group and 35 ± 23\xa0nmol/l in the vitamin d group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 155, 'D')]
S38-PMC5146866	PMC5146866	12/2016	S38-PMC5146866	['tested levels of Calcidiol [25(Oh)D] and Vitamin D components, including the Ergocalciferol (Vitamin D2) and Cholecalciferol (Vitamin D3) were Expressed in ng/ml.']	N/A	N/A	[('CHEBI_17933', 'calcidiol', 17, 'calcidiol'), ('CHEBI_71657', 'versiconol acetate', 28, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_4910', 'etomidate', 77, 'ergocalciferol'), ('CHEBI_28934', 'vitamin D2', 93, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 93, 'Vitamin D2'), ('CHEBI_52550', 'theopalauamide', 109, 'cholecalciferol'), ('CHEBI_33237', 'vitamin D4', 126, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 126, 'Vitamin D3'), ('GO_0010467', 'gene expression', 143, 'expressed')]
S59-PMC5146866	PMC5146866	12/2016	S59-PMC5146866	['as shown in table\xa01, mothers of infants with deficient and insufficient level of Vitamin D in cb were younger and had a greater number of Pregnancies as compared to mothers of infants with sufficient level of [25(Oh)D].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnancies'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 210, '25(OH ... D')]
S9-PMC5155676	PMC5155676	12/2016	S9-PMC5155676	['results:\n25(Oh)D at 34 weeks of Gestation was higher in the women randomized to Vitamin D (mean [sd], 67.7 [21.3] nmol/l) compared with placebo (43.1 [22.5] nmol/l; p< .001).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 32, 'gestation'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S68-PMC5155676	PMC5155676	12/2016	S68-PMC5155676	['maternal characteristics at baseline according to randomization groupplacebo1000-iu/d Cholecalciferoln422407Gestation (wk), mean (sd)15.9 (1.5)15.9 (1.5)maternal age (y), mean (sd)30.7 (5.4)30.7 (5.0)nulliparous (%)44.842.7current smoker (%)7.77.7bmi (kg/m2), median (iqr)25.4 (22.7–29.7)24.6 (22.2–28.6)height (cm), mean (sd)165.6 (6.6)165.5 (6.3)white ethnicity (%)94.895.625(Oh)D (nmol/l), median (iqr)44.4 (33.2–57.0)45.7 (34.3–57.8)\n\nmaternal 25(Oh)D status at 34 weeks of Gestation by randomization group\nmaternal 25(Oh)D at 34 weeks of Gestation was greater in the women randomized to Cholecalciferol (mean 67.7 nmol/l [sd 21.3 nmol/l]) compared with the placebo group (mean 43.1 nmol/l [sd 22.5 nmol/l], p< .0001); 83.3% of women randomized to Cholecalciferol achieved Vitamin D replete status at 34 weeks of Gestation (>50 nmol/l) compared with 35.6% in the placebo group ( p< .001).']	N/A	N/A	[('CHEBI_52815', 'cresyl violet', 86, 'Cholecalciferoln422407Gestation'), ('CHEBI_33010', 'chromide(1-)', 377, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 451, 'OH)D'), ('GO_0007565', 'female pregnancy', 478, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 520, '25(OH)D'), ('GO_0007565', 'female pregnancy', 543, 'gestation'), ('CHEBI_52550', 'theopalauamide', 592, 'cholecalciferol'), ('CHEBI_52550', 'theopalauamide', 752, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 777, 'vitamin D'), ('GO_0007565', 'female pregnancy', 817, 'gestation')]
S17-PMC5418719	PMC5418719	5/2017	S17-PMC5418719	['responses to different doses of Vitamin D supplementation and monitored supplementation of Vitamin D with serial measurement of 25 (Oh)D concentrations are limited in vlbw within a month after Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 128, '25 (OH)D'), ('GO_0007567', 'parturition', 193, 'birth')]
S24-PMC5418719	PMC5418719	5/2017	S24-PMC5418719	['study protocol\nat Birth, Serum calcium, phosphorus, alkaline phosphatase and 25(Oh)D concentrations were obtained from Cord Blood samples before Vitamin D supplementation was started.']	N/A	N/A	[('GO_0007567', 'parturition', 18, 'birth'), ('UBERON_0001977', 'blood serum', 25, 'serum'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 119, 'cord'), ('UBERON_0000178', 'blood', 124, 'blood'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
S57-PMC5418719	PMC5418719	5/2017	S57-PMC5418719	['five infants (10%) had sufficient 25(Oh)D levels in range of 30.1–80\xa0ng/ml at Birth, and 31 infants (72%) at 36\u2009±\u20091\xa0weeks pma achieved sufficient 25(Oh)D levels after Vitamin D supplementation.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 34, '25(OH ... D'), ('GO_0007567', 'parturition', 78, 'birth'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 146, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
S71-PMC5418719	PMC5418719	5/2017	S71-PMC5418719	['caption (table-wrap): table 1\n\ndemographic characteristicscharacteristicsall patients( n \u2009=\u200952)Cord 25(Oh)D concentrations <10\xa0ng/ml ( n \u2009=\u200920)Cord 25(Oh)D concentrations ≥10\xa0ng/ml ( n \u2009=\u200929)maternal age, years34.3\u2009±\u20093.432.4\u2009±\u20093.133.8\u2009±\u20094.0gdm6 (12%)5 (25%)1 (3%)*preeclampsia4 (8%)0 (0%)3 (10%)antenatal Steroid44 (85%)19 (95%)22 (79%)histological chorioamnionitis33 (64%)11 (55%)21 (72%)completed college38 (73)13 (65%)24 (83%)Birth during Vitamin D Synthesizing period30 (58%)7 (35%)20 (69%)†Gestational age (weeks)27.1\u2009±\u20092.527.5\u2009±\u20092.526.8\u2009±\u20092.6small Gestational age8 (15%)2 (10%)5 (17%)Birth weight (g)971.2\u2009±\u2009252.41045.5\u2009±\u2009271.8933.5\u2009±\u2009203.6birth length (cm)34.1\u2009±\u20093.534.3\u2009±\u20093.434.1\u2009±\u20093.6birth Head circumference (cm)24.6\u2009±\u20092.224.8\u2009±\u20092.324.5\u2009±\u20092.2male sex26 (50%)7 (35%)16 (55%)cesarean section40 (77%)18 (90%)20 (71%)apgar score at 5\xa0min5.1\u2009±\u20091.55.3\u2009±\u20091.74.9\u2009±\u20091.3rds47 (90%)17 (85%)27 (96%)pda35 (67%)15 (79%)19 (66%)Nec3 (6%)0 (0%)2 (7%)culture-proven sepsis17 (33%)5 (26%)11 (38%)bpd (≥ moderate)25 (48%)7 (37%)16 (55%)rop (≥ stage 2)24 (46%)8 (40%)14 (50%)ivh (≥ grade 2)6 (12%)4 (20%)2 (7%)Breast Milk with/without formula38 (73%)13 (65%)22 (76%)exclusively fortified Breast Milk13 (25%)5 (25%)8 (28%)ventilation days (d)24.1\u2009±\u200918.420.9\u2009±\u200918.120.9\u2009±\u200918.1hospital days (d)85.5\u2009±\u200933.277.6\u2009±\u200924.886.6\u2009±\u200928.3tpn days (d)47.1\u2009±\u200932.537.2\u2009±\u200922.747.2\u2009±\u200922.4\ndata are presented as n (%), median (range), or mean\u2009±\u2009sd\ngdm Gestational diabetes mellitus, rds Respiratory Distress syndrome, pda patent Ductus Arteriosus, nec necrotizing enterocolitis, bpd bronchopulmonary dysplasia, rop retinopathy of prematurity, Ivh Intraventricular hemorrhage, tpn total parenteral nutrition\n*p \u2009=\u20090.035 for the difference between cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml vs. ≥ 10\xa0ng/ml\n†p \u2009=\u20090.023 for the difference between Cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml vs. ≥ 10\xa0ng/ml\nall neonates received 800\xa0iu 25(Oh)D per day from first 2\xa0weeks of age.']	N/A	N/A	[('CHEBI_33252', 'atomic nucleus', 95, 'Cord'), ('UBERON_0000948', 'heart', 95, 'Cord'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 100, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 103, 'OH ... D'), ('CHEBI_33252', 'atomic nucleus', 143, 'Cord'), ('UBERON_0000948', 'heart', 143, 'Cord'), ('CHEBI_71657', 'versiconol acetate', 148, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 148, '25(OH ... D'), ('CHEBI_75977', '(S)-2-hydroxyhexadecanoic acid', 305, 'steroid44'), ('GO_0007567', 'parturition', 429, 'Birth'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('GO_0031319', 'detection of cAMP', 450, 'D synthesizing'), ('GO_0007565', 'female pregnancy', 495, 'Gestational'), ('GO_0007565', 'female pregnancy', 554, 'gestational'), ('GO_0007567', 'parturition', 590, 'Birth'), ('UBERON_0000033', 'head', 699, 'head'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 924, 'NEC3'), ('UBERON_0013538', 'Brodmann (1909) area 7', 1101, 'Breast milk'), ('UBERON_0013558', 'Brodmann (1909) area 27', 1179, 'breast milk13'), ('GO_0007565', 'female pregnancy', 1423, 'gestational'), ('UBERON_0003495', 'respiratory system arteriole', 1458, 'respiratory distress'), ('UBERON_0002254', 'thyroglossal duct', 1500, 'ductus arteriosus'), ('UBERON_2005050', 'palatocerebral artery', 1614, 'IVH'), ('UBERON_0006250', 'infundibular recess of 3rd ventricle', 1618, 'intraventricular'), ('CHEBI_71657', 'versiconol acetate', 1722, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1722, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 1810, 'cord'), ('CHEBI_33010', 'chromide(1-)', 1817, '(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1821, 'D'), ('CHEBI_71657', 'versiconol acetate', 1893, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 1896, 'OH)D')]
S74-PMC5418719	PMC5418719	5/2017	S74-PMC5418719	['after the Vitamin D supplementation, the Serum 25(Oh)D status at discharge in the two groups converged into increasing 25(Oh)D concentrations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D')]
S76-PMC5418719	PMC5418719	5/2017	S76-PMC5418719	['the proportion of infants with Vitamin D sufficiency was lower in those with cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml than in those with cord 25(Oh)D concentrations\u2009≥\u200910\xa0ng/ml at 36\u2009±\u20091\xa0weeks Pma (65% vs. 88%; p \u2009=\u20090.12; table\xa02).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 140, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 140, '25(OH)D'), ('CHEBI_34913', 'Phenbenzamine hydrochloride', 190, 'PMA')]
S83-PMC5418719	PMC5418719	5/2017	S83-PMC5418719	['the three infants in the Cord 25(Oh)D concentrations\u2009≥\u200910\xa0ng/ml group had a Vitamin D excess (85.5, 94 and 97.2\xa0ng/ml) at 36\u2009±\u20091\xa0weeks pma.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 25, 'cord'), ('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 30, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
S115-PMC5418719	PMC5418719	5/2017	S115-PMC5418719	['daily maternal (2000\xa0iu) and infant (800\xa0iu) Vitamin D supplementation attained a Serum 25(Oh)D\u2009>\u200930\xa0ng/ml in 80% of study infants at 4\xa0months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D')]
S48-PMC5489519	PMC5489519	6/2017	S48-PMC5489519	['Serum samples collected from fifteen nursing mothers’ were measured for 25(Oh)D levels to evaluate Vitamin D status in mother groups as described in methods.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 78, 'D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S35-PMC5524288	PMC5524288	7/2017	S35-PMC5524288	['new ob patients were offered a free bottle of bio-tech pharmacal, inc. (fayetteville, ar) Vitamin D supplements (5000 iu per capsule) at their first visit and personalized dosing recommendations were provided based on the result of their initial 25(Oh)D test using an algorithm of existing dose-response data [11].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 246, '25(OH)D')]
S90-PMC5524288	PMC5524288	7/2017	S90-PMC5524288	['there were no cases of Vitamin D toxicity based on elevated Serum calcium levels (≥11 mg/dl).10.1371/journal.pone.0180483.g004\n\ncaption (fig): fig 4\nPreterm Birth rates among women with low initial 25(Oh)D concentrations (<40 ng/ml at ≤20 weeks), comparing those with concentrations ≥40 ng/ml vs. those with concentrations <40 ng/ml on a follow-up test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0001977', 'blood serum', 60, 'serum'), ('GO_0007128', 'meiotic prophase I', 149, 'Preterm'), ('GO_0007567', 'parturition', 157, 'birth'), ('CHEBI_71657', 'versiconol acetate', 198, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 198, '25(OH)D')]
S13-PMC5537904	PMC5537904	7/2017	S13-PMC5537904	['maternal 25(Oh)D freely crosses the Placenta and is the only source of Vitamin D available to the developing fetus [3].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('UBERON_0001987', 'placenta', 36, 'placenta'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
S94-PMC5537904	PMC5537904	7/2017	S94-PMC5537904	['mother-offspring dyads were eligible for the analyses if offspring were Born ≥37 weeks Gestation, had 25(Oh)D measured in Cord Blood, and had at least one of the following: complete data on maternal Intake of Vitamin D during Pregnancy from Food and dietary supplements, body composition measured at Birth, or body composition measured Postnatally.']	N/A	N/A	[('GO_0007567', 'parturition', 72, 'born'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D'), ('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('GO_0007631', 'feeding behavior', 199, 'intake'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_33290', 'food', 241, 'food'), ('GO_0007567', 'parturition', 300, 'birth'), ('GO_0007565', 'female pregnancy', 336, 'postnatally')]
S167-PMC5537904	PMC5537904	7/2017	S167-PMC5537904	['for every 100 iu/day increase in Vitamin D from Food sources or dietary supplements, we observed a 0.6 nmol/l increase in Cord Blood 25(Oh)D. this is a substantially smaller increase than the 2.5 nmol/l increase per 100 iu/day benchmark that has been used to guide Vitamin D supplementation [62].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33290', 'food', 48, 'food'), ('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 139, 'D'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D')]
S65-PMC5546866	PMC5546866	8/2017	S65-PMC5546866	['in addition, in women randomized to Cholecalciferol, we assessed the relationship between the Snps and the change in Vitamin D using the residuals of 25(Oh)D at 34 weeks of Gestation Regressed on 25(Oh)D at 14 weeks of Gestation as the outcome.']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 36, 'cholecalciferol'), ('SO_0000694', 'SNP', 94, 'SNPs'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 150, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 156, 'D'), ('GO_0007565', 'female pregnancy', 173, 'gestation'), ('GO_0060033', 'anatomical structure regression', 183, 'regressed'), ('CHEBI_71657', 'versiconol acetate', 196, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 202, 'D'), ('GO_0007565', 'female pregnancy', 219, 'gestation')]
S65-PMC5659607	PMC5659607	10/2017	S65-PMC5659607	['third, we cross-classified the women using 25(Oh)D level at randomization (above or below 30 ng/ml) combined with the assigned treatment (Vitamin D or placebo).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 43, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 43, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
S95-PMC5659607	PMC5659607	10/2017	S95-PMC5659607	['there was no such association for women with 25(Oh)D level ≥30ng/ml randomized to Placebo or women with 25(Oh)D level <30ng/ml randomized to Vitamin D ( table 3 ).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 45, '25(OH)D'), ('CHEBI_26130', 'biological pigment', 82, 'placebo'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D')]
S119-PMC5659607	PMC5659607	10/2017	S119-PMC5659607	['the vdaart and copsac2010trials used different doses of Vitamin D, initiated the supplementation at different Pregnancy stages ranging from 10 to 26 weeks of Gestation, and enrolled pregnant women with divergent 25(Oh)D levels at entry into the trials.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 158, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 212, '25 ... OH ... D')]
S65-PMC5679631	PMC5679631	11/2017	S65-PMC5679631	['the analyses regarding maternal Vitamin D supplementation and maternal 25(Oh)D quintiles were performed on the entire population because the exposure of interest was Prenatal, i .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('GO_0007565', 'female pregnancy', 166, 'prenatal')]
S71-PMC5679631	PMC5679631	11/2017	S71-PMC5679631	['the categorical variables, quintiles of maternal 25(Oh)D and amount of maternal Vitamin D supplementation, were transformed into interval variables to conduct the tests for interaction, as well as the tests for linear trend performed with linear regression.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 49, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S86-PMC5679631	PMC5679631	11/2017	S86-PMC5679631	['finally, there was an expected difference among the quintiles in terms of season of Blood sampling in that the higher quintiles included a lower percentage of mothers giving blood during the winter season and a higher percentage in the summer.10.1371/journal.pone.0188011.t001\n\ncaption (table-wrap): table 1\ncharacteristics of the study population (n = 913).maternal multivitamin supplementation containing Vitamin D (n = 913)maternal Plasma 25(Oh)D nmol/l (n = 892)infant Vitamin D supplementation§(n = 616)none< 10 μg≥ 10 μgq 1q 2q 3q 4q 5yesno7.7–27.3#27.4–37.3#37.4–47.8#47.9–59.9#60.0–126.4#n = 350n = 144n = 41921.4 (4.3)&32.3 (2.9)&43.0 (3.2)&53.3 (3.5)&71.9 (10.9)&n = 441n = 165n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%) mode and place of Delivery Vaginal / home171 (48.9)71 (49.3)188 (44.9)80 (44.9)87 (48.6)80 (44.7)92 (51.7)78 (43.8)245 (55.6)93 (56.3)Vaginal / hospital137 (39.1)56 (38.9)174 (41.5)68 (38.2)74 (41.3)77 (43.0)63 (35.4)78 (43.8)157 (35.6)58 (35.2)c-section / hospital36 (10.3)12 (8.3)47 (11.2)21 (11.8)15 (8.4)19 (10.6)21 (11.8)18 (10.1)39 (8.8)14 (8.5)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 number of siblings none130 (37.1)68 (47.2)166 (39.6)71 (39.9)71 (39.7)73 (40.8)83 (46.7)61 (34.3)185 (42)46 (27.9)1153 (43.7)51 (35.4)197 (47.0)79 (44.4)79 (44.1)82 (45.8)72 (40.4)77 (43.2)189 (42.8)76 (46.1)2 or more66 (18.9)25 (17.4)56 (13.4)28 (15.7)28 (15.6)24 (13.4)23 (12.9)40 (22.5)66 (15)43 (26)missing1 (0.3)0001 (0.6)0001 (0.2)0 recruitment group conventional233 (66.6)66 (45.8)322 (76.8)114 (64)117 (65.4)121 (67.6)129 (72.5)132 (74.2)298 (67.6)54 (32.7)alternative117 (33.4)78 (54.2)97 (23.2)64 (36)62 (34.6)58 (32.4)49 (27.5)46 (25.8)143 (32.4)111 (67.3) maternal Vitamin D quintile 1104 (29.7)30 (20.8)44 (10.5)64 (14.5)40 (24.2)283 (23.7)30 (20.8)66 (15.8)87 (19.7)38 (23)359 (16.9)25 (17.4)95 (22.7)88 (20)24 (14.5)460 (17.1)22 (15.3)96 (22.9)98 (22.2)28 (17)538 (10.9)30 (20.8)110 (26.2)96 (21.8)29 (17.7)missing6 (1.7)7 (4.9)8 (1.9)8 (1.8)6 (3.6) sex male196 (56)63 (43.8)200 (47.7)102 (57.3)87 (48.6)93 (52)78 (43.8)89 (50)219 (49.7)81 (49.1)female154 (44)81 (56.2)219 (52.3)76 (42.7)92 (51.4)86 (48)100 (56.2)89 (50)222 (50.3)84 (50.9) vaginitis (last month of Pregnancy) no319 (91.2)123 (85.4)372 (88.8)156 (87.6)161 (89.9)163 (91)162 (91)153 (86)409 (92.7)143 (86.7)yes25 (7.1)16 (11.1)37 (8.8)13 (7.3)15 (8.4)13 (7.3)14 (7.9)21 (11.8)32 (7.3)22 (13.3)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 mode of infant Feeding Breast Feeding243 (69.4)105 (72.9)268 (64.0)107 (60.1)125 (69.8)114 (63.7)128 (71.9)128 (71.9)bottle feeding80 (22.9)25 (17.4)103 (24.6)52 (29.2)39 (21.8)50 (27.9)29 (16.3)34 (19.1)combination feeding26 (7.4)14 (9.7)47 (11.2)19 (10.7)15 (8.4)15 (8.4)21 (11.8)15 (8.4)missing1 (0.3)01 (0.2)00001 (0.6) season of maternal Blood sampling winter89 (50)69 (38.6)49 (27.4)41 (23)22 (12.4)spring54 (30.3)51 (28.5)46 (25.7)31 (17.4)16 (8.9)summer8 (4.5)23 (12.8)40 (22.3)66 (37.1)82 (46.1)autumn27 (15.2)36 (20.1)44 (24.6)40 (22.5)58 (32.6)\n§only Breast Fed children;\n#range;\n&mean (sd)\n\nmaternal 25(Oh)D and use of multivitamin supplements containing Vitamin D\nmaternal 25(Oh)D concentrations of the entire group ranged from 7.7 to 126.3 nmol/l with a mean of 44.3, sd 18.3 nmol/l.']	N/A	N/A	"[('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_27300', 'vitamin D', 407, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 435, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 442, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 442, '25(OH ... D'), ('CHEBI_28384', 'vitamin K', 473, 'Vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 481, 'D'), ('GO_0007586', 'digestion', 756, 'Delivery'), ('UBERON_0000970', 'eye', 765, 'Vaginal'), ('UBERON_0000970', 'eye', 872, 'Vaginal'), ('CHEBI_28384', 'vitamin K', 1733, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 2237, 'Pregnancy'), ('GO_0007631', 'feeding behavior', 2512, 'Feeding'), ('UBERON_0000310', 'breast', 2520, 'Breast'), ('GO_0070479', ""nuclear-transcribed mRNA catabolic process, 5'-3' exonucleolytic nonsense-mediated decay"", 2527, 'Feeding243'), ('UBERON_0000178', 'blood', 2840, 'Blood'), ('GO_0007567', 'parturition', 3059, 'breast'), ('UBERON_0000310', 'breast', 3059, 'breast'), ('GO_0007631', 'feeding behavior', 3066, 'fed'), ('CHEBI_71657', 'versiconol acetate', 3109, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 3109, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 3164, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 3183, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 3189, 'D')]"
S87-PMC5679631	PMC5679631	11/2017	S87-PMC5679631	['the relationship between maternal 25(Oh)D and maternal use of multivitamin supplements containing Vitamin D is shown intable 2.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 34, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
S4-PMC5685050	PMC5685050	10/2014	S4-PMC5685050	"[""Vitamin D2(Ergocalciferol), from dietary sources or supplements, and Vitamin D3Are Metabolized in the Liver to 25-Hydroxyvitamin D (25(Oh)D), which is the major circulating form of Vitamin D and is used to determine an Individual's Vitamin D status[1].""]"	N/A	N/A	"[('CHEBI_28934', 'vitamin D2', 0, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin D2'), ('CHEBI_4910', 'etomidate', 11, 'ergocalciferol'), ('CHEBI_66036', ""(2S)-2'-hydroxy-7,8,3',4',5'-pentamethoxyflavan"", 69, 'vitamin D3are'), ('PR_000017209', 'utrophin', 69, 'vitamin D3are'), ('GO_0008152', 'metabolic process', 83, 'metabolized'), ('UBERON_0002107', 'liver', 102, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 111, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('NCBITaxon_1', 'root', 219, 'individual'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin D')]"
S15-PMC5685050	PMC5685050	10/2014	S15-PMC5685050	['[12]conducted the largest-scale examination of Vitamin D status in thai population and reported a 45.2% prevalence rate of Vitamin D insufficiency, defined as Serum 25(Oh)D level\xa0<\xa030\xa0ng/ml (<75\xa0nmol/l) a 5.7% prevalence rate of Vitamin D deficiency, defined as Serum 25(Oh)D level <20\xa0ng/ml (<50\xa0nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('UBERON_0001977', 'blood serum', 159, 'serum'), ('CHEBI_71657', 'versiconol acetate', 165, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 165, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('UBERON_0001977', 'blood serum', 262, 'serum'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 268, '25(OH)D')]
S97-PMC5706533	PMC5706533	11/2017	S97-PMC5706533	['the 25(Oh)D response to supplemental Vitamin D was not enhanced in trial populations with low mean baseline 25(Oh)D (<30 nmol/l) (tables s1 and s2 in appendix 10).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 10, 'D'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 108, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 111, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 114, 'D')]
S100-PMC5706533	PMC5706533	11/2017	S100-PMC5706533	['caption (table-wrap): table 3\n\nweighted mean differences (wmd) from primary meta-analyses of effects of Vitamin D supplementation during Pregnancy on maternal and neonatal/infant outcomesoutcomestrialsintervention-control comparisonsparticipantswmd (intervention versus control) (95% ci)i2(%) maternal Serum 25(Oh)D concentration at/near Delivery (nmol/l)3242570632.91*(27.19 to 38.62)96*neonatal/infant Birth weight (g ) 3037527358.33*(18.88 to 97.78)43*Birth length (cm)192138990.19 (−0.08 to 0.47)62*Head circumference at Birth (cm)171837910.13 (−0.05 to 0.30)63*Cord Serum 25(Oh)D concentration (nmol/l)2028298827.73*(21.57 to 33.88)96*Gestational age at Birth (weeks)19233214−0.01 (−0.19 to 0.16)54*neonatal bone Mineral content (g)226901.09 (−0.64 to 2.81)0infant bone Mineral content (g)1252−43.00*(−67.25 to −18.75)0neonatal bone Mineral density (g/cm2)226900.00 (−0.003 to 0.004)0infant bone Mineral density (g/cm2)1252−0.04*(−0.06 to −0.03)0length at age 1 year (cm)222511.30*(0.54 to 2.06)40weight at age 1 year (g)22252290.62 (−5.04 to 586.29)47head circumference at age 1 year (cm)222480.09 (−0.28 to 0.45)0length for age z score at 1 year†231860.31 (−0.04 to 0.66)0weight for age z score at 1 year†231870.13 (−0.19 to 0.45)0head circumference for age z score at 1 year†231830.12 (−0.18 to 0.42)0\n*p<0.05.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0001977', 'blood serum', 302, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 308, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 308, '25 ... OH ... D'), ('GO_0007567', 'parturition', 338, 'delivery'), ('GO_0007567', 'parturition', 404, 'Birth'), ('GO_0007567', 'parturition', 455, 'Birth'), ('UBERON_0000033', 'head', 503, 'Head'), ('GO_0007567', 'parturition', 525, 'birth'), ('UBERON_0000948', 'heart', 566, 'Cord'), ('UBERON_0001977', 'blood serum', 571, 'serum'), ('CHEBI_71657', 'versiconol acetate', 577, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 583, 'D'), ('GO_0007565', 'female pregnancy', 640, 'Gestational'), ('GO_0007567', 'parturition', 659, 'birth'), ('CHEBI_46662', 'mineral', 718, 'mineral'), ('CHEBI_46662', 'mineral', 775, 'mineral'), ('CHEBI_46662', 'mineral', 838, 'mineral'), ('CHEBI_46662', 'mineral', 901, 'mineral')]
S8-PMC5732505	PMC5732505	12/2017	S8-PMC5732505	['of the study population, 97% were Vitamin D sufficient [25(Oh)D\u2009≥\u200950\xa0nmol/l].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D')]
S45-PMC5732505	PMC5732505	12/2017	S45-PMC5732505	['the quality and accuracy of the Serum 25(Oh)D analysis is validated on an ongoing basis by participation in the Vitamin D external quality assessment scheme (deqas, charing cross hospital, london, uk).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 32, 'serum'), ('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 38, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
S87-PMC5732505	PMC5732505	12/2017	S87-PMC5732505	['p -values refer to differences between the groupsmaternal characteristics n non-gdm n gdm p valueage at Delivery (y)64231.4\xa0±\xa04.38132.7\xa0±\xa04.50.018level of educationa6325.0\xa0±\xa01.3794.7\xa0±\xa01.40.051parity6401.5\xa0±\xa00.7811.5\xa0±\xa00.70.275prepregnancy smoking, number of cigarettes daily6251.2\xa0±\xa03.7762.0\xa0±\xa04.60.064alcohol consumption before Pregnancy, portion/wk.6251.9\xa0±\xa02.0782.3\xa0±\xa03.50.755prepregnancy height (cm)642166.3\xa0±\xa06.081165.9\xa0±\xa05.40.398prepregnancy weight (kg)63163.5\xa0±\xa010.28172.1\xa0±\xa013.5<0.001prepregnancy bmi (kg/m2)63923.0\xa0±\xa03.58126.2\xa0±\xa04.8<0.001duration of Gestation at ogtt (wk)32326.3\xa0±\xa04.38025.9\xa0±\xa05.90.774duration of Gestation at Pregnancy Blood sampling (wk)64211.3\xa0±\xa01.98111.2\xa0±\xa02.20.089duration of Gestation at Delivery (wk)64240.2\xa0±\xa01.18140.1\xa0±\xa01.10.410pregnancy 25(Oh)D (nmol/l)64281.9\xa0±\xa019.58180.0\xa0±\xa021.20.417ucb 25(Oh)D (nmol/l)64280.1\xa0±\xa020.08178.4\xa0±\xa018.80.448supplemental Vitamin D intake during Pregnancy ( μ g/d)62115.5\xa0±\xa016.67613.5\xa0±\xa010.80.162cumulative Gestational weight gain atb(kg)0.093\u2003first measurement5801.7\xa0±\xa00.5741.6\xa0±\xa00.5\u200312th Gestational week5803.8\xa0±\xa01.0743.6\xa0±\xa01.1\u200320th Gestational week5806.3\xa0±\xa00.8746.2\xa0±\xa00.8\u200330th Gestational week5809.7\xa0±\xa00.5749.7\xa0±\xa00.4\u2003last measurement58013.8\xa0±\xa00.47413.7\xa0±\xa00.3\ngdm Gestational diabetes mellitus, 25(Oh)D 25-Hydroxy Vitamin D, ucb Umbilical cord Blood\nvalues are means ± sd\nascale from 1\u2009=\u2009lower secondary education to 6\u2009=\u2009first or second stage of tertiary education\nbvalues are adjusted for duration of Gestation\nindependent sample t-tests, mann-whitney u-tests, repeated measures anova or the pearson chi-square test, when appropriate, were applied to compare maternal characteristics between gdm and non-gdm mothers.']	N/A	N/A	[('GO_0007567', 'parturition', 104, 'delivery'), ('GO_0007565', 'female pregnancy', 330, 'pregnancy'), ('GO_0007565', 'female pregnancy', 560, 'gestation'), ('GO_0007565', 'female pregnancy', 624, 'gestation'), ('GO_0007565', 'female pregnancy', 637, 'pregnancy'), ('UBERON_0000178', 'blood', 647, 'blood'), ('GO_0007565', 'female pregnancy', 708, 'gestation'), ('GO_0007567', 'parturition', 721, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 774, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 826, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 832, 'D'), ('CHEBI_27300', 'vitamin D', 887, 'vitamin D'), ('GO_0007565', 'female pregnancy', 911, 'pregnancy'), ('GO_0007565', 'female pregnancy', 972, 'gestational'), ('GO_0007565', 'female pregnancy', 1055, 'gestational'), ('GO_0007565', 'female pregnancy', 1100, 'gestational'), ('GO_0007565', 'female pregnancy', 1145, 'gestational'), ('GO_0007565', 'female pregnancy', 1231, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1262, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1270, '25-hydroxy vitamin D'), ('UBERON_0007118', 'umbilicus', 1296, 'umbilical'), ('UBERON_0000178', 'blood', 1311, 'blood'), ('GO_0007565', 'female pregnancy', 1469, 'gestation')]
S98-PMC5732505	PMC5732505	12/2017	S98-PMC5732505	['results\nin the study population 97% were Vitamin D sufficient [25(Oh)D\u2009>\u200950\xa0nmol/l] in both mothers and newborns, while optimal Vitamin D status [25(Oh)D above 80\xa0nmol/l] was seen in 52% of the mothers and 45% of the newborns.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 69, 'D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 152, 'D')]
S128-PMC5732505	PMC5732505	12/2017	S128-PMC5732505	['caption (table-wrap): table 2\n\nindependent effect of maternal factors on Birth sizeabirth weight (sds)Birth length (sds)Head circumference (sds)bponderal index (z-score)cmaternal factors np value p value p value p valueprepregnancy bmi 0.020 0.2010.3640.719\u2003underweight19−0.49\u2009±\u20090.17−0.36\u2009±\u20090.19−0.34\u2009±\u20090.22−0.12\u2009±\u20090.23\u2003normal weight494−0.30\u2009±\u20090.03−0.23\u2009±\u20090.04−0.14\u2009±\u20090.04−0.01\u2009±\u20090.05\u2003overweight117−0.13\u2009±\u20090.07−0.12\u2009±\u20090.08−0.04\u2009±\u20090.090.08\u2009±\u20090.09\u2003obese44−0.05\u2009±\u20090.12−0.01\u2009±\u20090.130.03\u2009±\u20090.140.08\u2009±\u20090.16gestational weight gain <0.0010.006 0.1860.505\u2003inadequate164−0.43\u2009±\u20090.06−0.37\u2009±\u20090.07−0.23\u2009±\u20090.07−0.05\u2009±\u20090.08\u2003adequate261−0.28\u2009±\u20090.05−0.20\u2009±\u20090.05−0.11\u2009±\u20090.06−0.02\u2009±\u20090.06\u2003excessive242−0.12\u2009±\u20090.05−0.09\u2009±\u20090.06−0.05\u2009±\u20090.060.07\u2009±\u20090.07prepregnancy smoking 0.021 0.2270.0930.173\u2003yes101−0.43\u2009±\u20090.08−0.30\u2009±\u20090.09−0.27\u2009±\u20090.10−0.13\u2009±\u20090.11\u2003no573−0.23\u2009±\u20090.03−0.18\u2009±\u20090.04−0.09\u2009±\u20090.040.03\u2009±\u20090.04maternal education0.9720.6700.7210.634\u2003higher513−0.26\u2009±\u20090.03−0.19\u2009±\u20090.04−0.11\u2009±\u20090.04−0.00\u2009±\u20090.05\u2003lower161−0.26\u2009±\u20090.06−0.23\u2009±\u20090.07−0.14\u2009±\u20090.080.04\u2009±\u20090.08parity <0.001<0.0010.0070.027 \u2003nullipara431−0.40\u2009±\u20090.04−0.32\u2009±\u20090.04−0.20\u2009±\u20090.05−0.05\u2009±\u20090.05\u2003secundipara185−0.03\u2009±\u20090.05−0.05\u2009±\u20090.06−0.03\u2009±\u20090.070.18\u2009±\u20090.07\u2003multipara580.04\u2009±\u20090.100.22\u2009±\u20090.110.17\u2009±\u20090.12−0.07\u2009±\u20090.13gestational diabetes mellitus0.0630.5590.3510.075\u2003yes76−0.10\u2009±\u20090.09−0.15\u2009±\u20090.10−0.02\u2009±\u20090.110.21\u2009±\u20090.12\u2003no598−0.28\u2009±\u20090.03−0.21\u2009±\u20090.03−0.13\u2009±\u20090.04−0.02\u2009±\u20090.04pregnancy 25(Oh)D concentration 0.010 0.0950.3980.236\u2003suboptimal (<80\xa0nmol/l)333−0.34\u2009±\u20090.04−0.26\u2009±\u20090.05−0.15\u2009±\u20090.05−0.04\u2009±\u20090.06\u2003optimal (≥80\xa0nmol/l)341−0.19\u2009±\u20090.04−0.15\u2009±\u20090.05−0.09\u2009±\u20090.050.05\u2009±\u20090.06ucb 25(Oh)D concentration0.1490.486 0.003 0.234\u2003suboptimal (<80\xa0nmol/l)369−0.22\u2009±\u20090.04−0.18\u2009±\u20090.04−0.02\u2009±\u20090.050.05\u2009±\u20090.05\u2003optimal (≥80\xa0nmol/l)305−0.31\u2009±\u20090.04−0.23\u2009±\u20090.05−0.24\u2009±\u20090.05−0.05\u2009±\u20090.06\n25(Oh)D 25-Hydroxy Vitamin D, ucb Umbilical Cord Blood\nvalues are adjusted mean\u2009±\u2009sem.']	N/A	N/A	[('GO_0007567', 'parturition', 73, 'birth'), ('GO_0007567', 'parturition', 102, 'Birth'), ('UBERON_0000033', 'head', 120, 'Head'), ('CHEBI_71657', 'versiconol acetate', 1405, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1405, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1598, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1791, 'OH)D'), ('CHEBI_43141', '3-hydroxypropoxy group', 1796, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 1807, 'vitamin D'), ('UBERON_0002331', 'umbilical cord', 1822, 'umbilical cord'), ('UBERON_0000178', 'blood', 1837, 'blood')]
S33-PMC5827025	PMC5827025	2/2018	S33-PMC5827025	['caption (table-wrap): table 1\n\ndemographic characteristics of 3598 mothers.demographic variablesgestational Vitamin D status1p -value2deficiencyinsufficiencysufficiencypregnant women [n (%)]1397 (38.83)1260 (35.02)941 (26.15)maternal age [years, n (%)]\xa0\xa0<25\xa0\xa025–34\xa0\xa0≥35220 (15.75)1131 (80.96)46 (3.29)194 (15.40)1022 (81.11)44 (3.49)147 (15.62)768 (81.61)26 (2.77)0.909maternal bmi [kg/m2, n (%)]\xa0\xa0underweight (<18.5)\xa0\xa0normal weight (18.5–22.9)\xa0\xa0overweight (≥23.0)333 (23.84)925 (66.21)139 (9.95)271 (21.51)859 (68.17)130 (10.32)168 (17.85)649 (68.97)124 (13.18)0.003season of Blood sample [n (%)]\xa0\xa0spring\xa0\xa0summer\xa0\xa0fall\xa0\xa0winter477 (34.14)311 (22.26)279 (19.97)330 (23.62)468 (37.14)271 (21.51)275 (21.83)246 (19.52)371 (39.43)225 (23.91)193 (20.51)152 (16.15)0.001periconceptional Multivitamin use [n (%)]\xa0\xa0no\xa0\xa0less than one month\xa0\xa0more than one month1220 (87.33)97 (6.94)80 (5.73)1033 (81.98)112 (8.89)115 (9.13)743 (78.96)81 (8.61)117 (12.43)<0.001family monthly income (rmb/yuan) [n (%)]\xa0\xa0low (<2000)\xa0\xa0middle (2000–3999)\xa0\xa0high (≥4000)611 (43.74)590 (42.23)196 (14.03)557 (44.21)516 (40.95)187 (14.84)432 (45.91)372 (39.53)137 (14.56)0.746parity [n(%)]\xa0\xa01 >11345 (96.87)60 (3.13)1238 (96.97)51 (3.03)927 (96.58)37 (3.42)0.854gestational week of Blood sample [w, n (%)]\xa0\xa0first-trimester (<13)\xa0\xa0second-trimester (13–27)519 (37.15)878 (62.85)444 (35.24)816 (64.76)337 (35.81)604 (64.19)0.575\n125(Oh)D < 20\u2009ng/ml for deficiency; 20\u2009≤\u200925(Oh)D < 30\u2009ng/ml for insufficiency; 25(Oh)D ≥ 30\u2009ng/ml for sufficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('UBERON_0000178', 'blood', 577, 'blood'), ('CHEBI_7025', 'mupirocin', 781, 'multivitamin'), ('UBERON_0000178', 'blood', 1247, 'blood'), ('CHEBI_84177', '14-HPDHE', 1391, '125(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1432, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1470, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1470, '25(OH)D')]
S142-PMC5827025	PMC5827025	2/2018	S142-PMC5827025	['Gestational Vitamin D status was divided into three groups according to following criteria: 25(Oh)D <20\u2009ng/ml for vdd, 20\u2009≤\u200925(Oh)D <30\u2009ng/ml for vitamin insufficiency (vdi), and 25(Oh)D ≥30\u2009ng/ml for Vitamin D sufficiency (vds)5,14.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 92, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 95, 'OH ... D'), ('CHEBI_33010', 'chromide(1-)', 126, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 179, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 185, 'D'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D')]
S14-PMC5941617	PMC5941617	5/2018	S14-PMC5941617	['Vitamin D2And D3Are transported by Vitamin D binding protein to the Liver, where they are 25-hydroxylated by the Vitamin D-25-hydroxylase (Cyp2R1) to produce 25-Hydroxyvitamin D [25(Oh)D], the major circulating Vitamin D Metabolite which is used to evaluate individual Vitamin D status.']	N/A	N/A	[('CHEBI_67916', '2alpha,3beta,23-trihydroxylup-20(29)-en-28-oic acid', 0, 'Vitamin D2and D3are'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D2and D3are'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('UBERON_0002107', 'liver', 68, 'liver'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 139, 'CYP2R1'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 158, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 221, 'metabolite'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]
S15-PMC5941617	PMC5941617	5/2018	S15-PMC5941617	['then 25(Oh)D reaches the Kidney, where it undergoes a further hydroxylation by 25(Oh)D-1α-hydroxylase (Cyp27B1) into 1,25-Dihydroxyvitamin D [1,25(Oh)2D or Calcitriol], the bioactive hormonal form of Vitamin D [2,4].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 5, '25(OH)D'), ('UBERON_0002113', 'kidney', 25, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000006101', 'cytochrome P450 1A1', 103, 'CYP27B1'), ('CHEBI_67472', '15-epi-lupulin B', 117, '1,25-dihydroxyvitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 142, '1,25(OH)2D'), ('CHEBI_17823', 'calcitriol', 156, 'calcitriol'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]
S447-PMC5941617	PMC5941617	5/2018	S447-PMC5941617	['regarding dose regimens, both oral doses of 2000\xa0iu/day of Vitamin D3And 50000\xa0iu/week of Vitamin D2For 6\xa0weeks were well-tolerated and superior to 2000\xa0iu/day of Vitamin D2In raising Serum 25(Oh)D concentration ibd patients with Vitamin D deficiency [410].']	N/A	N/A	[('CHEBI_61991', 'maltotriose trisaccharide', 59, 'vitamin D3and'), ('PR_000027594', 'histone H3', 59, 'vitamin D3and'), ('CHEBI_27364', 'zinc molecular entity', 90, 'vitamin D2for'), ('PR_000017209', 'utrophin', 90, 'vitamin D2for'), ('CHEBI_33229', 'vitamin (role)', 163, 'vitamin D2in'), ('PR_000017255', 'Vang-like protein 1', 163, 'vitamin D2in'), ('UBERON_0001977', 'blood serum', 184, 'serum'), ('CHEBI_71657', 'versiconol acetate', 190, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 190, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D')]
S575-PMC5941617	PMC5941617	5/2018	S575-PMC5941617	['studies with daily or weekly regimens\nin Vitamin D deficient infants younger than 2\xa0years, either 2000\xa0iu of Vitamin D2Or Vitamin D3Daily or 50000\xa0iu of Vitamin D2Weekly for 6\xa0weeks equally increased Serum 25(Oh)D levels [515].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27329', 'xanthosine phosphate', 109, 'vitamin D2or'), ('PR_000017209', 'utrophin', 109, 'vitamin D2or'), ('CHEBI_63717', 'tenofovir disoproxil', 122, 'vitamin D3daily'), ('CHEBI_83468', 'isoproturon-monodemethyl', 153, 'vitamin D2weekly'), ('UBERON_0001977', 'blood serum', 200, 'serum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 206, '25(OH)D')]
S17-PMC5956785	PMC5956785	5/2018	S17-PMC5956785	['Cytochrome P450 27B1 (Cyp27B1) is the enzyme required to synthesize 1,25-Dihydroxyvitamin D (1,25(Oh)2D), the active form of Vitamin D, from circulating 25-Hydroxyvitamin D (25(Oh)D).']	N/A	N/A	[('CHEBI_4056', 'cytochrome', 0, 'Cytochrome'), ('PR_000006139', 'cytochrome P450 4F12', 0, 'Cytochrome p450 27B1'), ('PR_000006101', 'cytochrome P450 1A1', 22, 'CYP27B1'), ('CHEBI_67472', '15-epi-lupulin B', 68, '1,25-dihydroxyvitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 93, '1,25(OH)2D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 153, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 174, '25(OH)D')]
S80-PMC5956785	PMC5956785	5/2018	S80-PMC5956785	['2001 39°n [40]jian\u2009=\u200910 (6f)13.1\u2009±\u20092.553.9\u2009±\u20098.5all patients were Vitamin D replete 25(Oh)D\u2009>\u200917.5\xa0nmol/l, most were measured between february to may.missouri, usa hillman et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 84, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 84, '25(OH ... D')]
S93-PMC5956785	PMC5956785	5/2018	S93-PMC5956785	['active disease or frequent flare-ups resulted in lower Vitamin D than non-active and no frequent flare-ups.control group 25(Oh)D 74.4\u2009±\u200928.0\xa0nmol/l p \u2009<\u20090.005.intake jia 164\u2009±\u200984\xa0iu/day control 160\u2009±\u200972\xa0iu/day.new delhi, india dey et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D')]
S102-PMC5956785	PMC5956785	5/2018	S102-PMC5956785	['2000 51°n [49]jca n \u2009=\u200934 (23f)9.2 (4.6–13.6)estimated from graph\xa045 (14.5–62.5)Vitamin D status was significantly lower in jca patients than age-matched controls before treatment, Steroid-treated children have low Vitamin D. all but three children received Corticosteroids.control group 25(Oh)D estimate 75\xa0nmol/l.florence, italy falcini et al.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 80, 'Vitamin D'), ('CHEBI_35341', 'steroid', 181, 'Steroid'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_50850', 'etabonate ester', 258, 'corticosteroids'), ('CHEBI_71657', 'versiconol acetate', 288, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 288, '25(OH ... D')]
S5-PMC6011374	PMC6011374	6/2018	S5-PMC6011374	['results\nmean Serum 25(Oh)D in all women was 68.1\u2009±\u200927.1\xa0nmol/l and 28% ( n \u2009=\u2009772) were considered Vitamin D deficient (<\u200950\xa0nmol/l).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 13, 'serum'), ('CHEBI_71657', 'versiconol acetate', 19, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 19, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S51-PMC6011374	PMC6011374	6/2018	S51-PMC6011374	['briefly, Vitamin D concentrations were standardized by taking the difference of 25(Oh)D concentration to the average 25(Oh)D concentration of the corresponding month.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 117, '25(OH)D')]
S78-PMC6011374	PMC6011374	6/2018	S78-PMC6011374	['when women were categorised based on clinical definitions of Vitamin D deficiency and Serum 25(Oh)D between 50 and 75\xa0nmol/l used as the reference, no significant relationship between Vitamin D status and adverse Pregnancy outcome was found (table2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 92, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy')]
S104-PMC6011374	PMC6011374	6/2018	S104-PMC6011374	['the Placenta Expresses all the necessary components to convert 25(Oh)D to the active form and thus utilise active Vitamin D either locally or in a paracrine manner [45,47].']	N/A	N/A	[('UBERON_0001987', 'placenta', 4, 'placenta'), ('GO_0010467', 'gene expression', 13, 'expresses'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
S16-PMC6011374	PMC6011374	6/2018	S16-PMC6011374	['Vitamin D status is determined by measuring circulating Serum levels of 25-Hydroxy Vitamin D2\u2009+\u20093(25(Oh)D).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 56, 'serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 72, '25-hydroxy'), ('CHEBI_28934', 'vitamin D2', 83, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 83, 'vitamin D2'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D')]
